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Abstract 
Background: Endometrial carcinoma is the fourth most common cancer in European 
women, and incidence is increasing. No major improvements in treatment or survival 
have been achieved over the last decades, and an individualized treatment approach 
may improve the likelihood of a beneficial outcome for endometrial carcinoma 
patients. Identifying robust biomarkers that can improve risk-stratification and help 
select patients likely to benefit from specific treatments is vital. There is also a need 
for representative preclinical models in order to discover and validate new targeted 
therapies. 
 
Aim: To investigate potential new biomarkers in endometrial carcinoma, and to 
develop robust and reliable preclinical models to improve translational research. 
 
Material and methods: Endometrial carcinoma cell lines or patient derived primary 
tumor cells were implanted in the uterus of female mice to generate orthotopic 
endometrial carcinoma mouse models. We then applied several advanced imaging 
techniques to monitor development of disease in these models, including optical 
molecular imaging (OMI), magnetic resonance imaging (MRI) and positron emission 
tomography/computed tomography (PET/CT).  
Patients treated for endometrial carcinoma have been prospectively entered in a 
biobank of gynaecological malignancies and clinicopathological data, imaging data 
and biological samples have been collected. Tissue samples were evaluated by 
immunohistochemistry and microarray in order to explore expression of 
asparaginase-like protein 1 (ASRGL1) in endometrial carcinoma, relating the level of 
ASRGL1 to survival as well as imaging- and clinicopathological parameters.  
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Results: Bioluminescent imaging (BLI), MRI, and PET/CT using fluorine-18-
fluorodeoxyglucose (18F-FDG) or fluorine-18-fluorothymidine (18F-FLT) as tracer 
were all found to be feasible methods for monitoring of disease in orthotopic mouse 
models of endometrial carcinoma. With the exception of BLI, these imaging 
modalities were also demonstrated to visualize uterine tumors in patient derived 
xenografts (PDX) (Paper I). 
 
Epithelial adherence molecule (EpCAM) was found to be highly expressed in both 
endometrial carcinoma cell lines and in hysterectomy specimens from patients 
diagnosed with endometrial carcinoma. Near infrared fluorescence (NIRF) imaging 
using an Alexa 680 fluorophore (AF680)-conjugated anti-EpCAM antibody and BLI 
generated comparable images of uterine tumors in cell line based orthotopic 
endometrial carcinoma mouse models. EpCAM-AF680 NIRF was however superior 
to BLI in early delineation of metastatic disease. EpCAM-AF680 NIRF imaging was 
found to visualize uterine tumors in multiple orthotopic PDX models, with better 
contrast and earlier detection of tumors compared to 18F-FDG PET/CT imaging. 
Additionally, in vivo EpCAM-AF680 NIRF imaging accurately depicted a non-
significant therapeutic response following treatment with paclitaxel or trastuzumab in 
an orthotopic PDX model of endometrial carcinoma. (Paper II). 
 
Low ASRGL1 protein expression in endometrial carcinoma hysterectomy samples 
was validated as a strong prognostic biomarker with independent survival impact, 
both in the whole patient cohort and in patients diagnosed with endometrioid 
endometrial carcinoma. Low ASRGL1 mRNA level was found to be significantly 
associated with poor outcome. ASRGL1 expression was mainly intact in the 
precursor lesion complex atypical hyperplasia (CAH), while the majority of 
metastatic lesions had lost ASRGL1 expression (Paper III).   
 
Similar expression of ASRGL1 in corresponding curettage and hysterectomy samples 
were observed in 85% of patients where ASRGL1 status in post-operative specimens 
was known. Low expression of ASRGL1 in curettage was found to independently 
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predict poor outcome in the whole patient cohort, as well as in patients with 
presumed low risk curettage histology. Significant associations between low 
ASRGL1 expression and preoperatively assessed features of aggressive disease were 
observed, including high-risk curettage histology, hormone receptor loss in curettage, 
and large tumor size on MRI. Low ASRGL1 expression in curettage was also found 
to be an independent predictor of lymph node metastases (Paper IV). 
 
Conclusions: We have successfully generated orthotopical mouse models of 
endometrial carcinoma, including PDXs with different histological backgrounds, and 
demonstrated that tumor development and response to treatment can be monitored by 
multiple advanced small animal imaging techniques. Low expression of ASRGL1 in 
hysterectomy samples has been validated as an independent prognostic biomarker in 
endometrial carcinoma, and we suggest ASRGL1 expression in curettage as a 
promising pre-operative biomarker with a potential to improve risk-stratification and 
surgical planning. 
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1.1 Endometrial carcinoma 
The uterus is the major component of the female reproductive system, and consists of 
three distinct layers; an outer layer of peritoneum (serosa), a thick muscular layer 
(myometrium), and an inner mucosal lining (endometrium) including glands and 
stromal cells. Endometrial carcinomas originate from epithelial cells in the 
endometrium, and may potentially invade the surrounding myometrium and 
metastasize to local and distant sites (1). Despite the high number of patients 
diagnosed with endometrial carcinoma worldwide, there has been less research 
focusing on this malignancy compared to several other cancers (i.e. breast cancer). 
The mechanisms of endometrial carcinoma establishment and progression are yet not 
fully understood, and increasing this knowledge would be beneficial. Another 
problem is that current disease classification systems are suboptimal, thus making 
risk-stratification and planning of treatment difficult. Additionally, there is a dire 
need of better treatment strategies for patients with advanced and recurrent disease. 
More high-quality research is thus needed to help solve these issues and to improve 




Endometrial carcinoma has the 6th highest cancer incidence in women worldwide, and 
is the 4th most common female cancer in Europe after breast, colorectal, and lung 
cancer (2). Endometrial carcinoma is not as common in less developed countries, 
indicating that environmental factors contribute to disease development. In Norway, 
774 new cases of endometrial carcinoma were recorded in 2016 (3). An increasing 
incidence of endometrial carcinoma has been observed over the last decades (Figure 
1), and can be explained by several factors, including higher life-expectancy and an 
increasing rate of obesity. It is estimated that 1 in 40 women will develop endometrial 
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carcinoma during their lifetime, and prognostic models suggest that between 1016-
1257 new cases of endometrial carcinoma will be diagnosed annually in Norway in 
2025 (4).  
 
Figure 1. Age standardized incidence rates of endometrial carcinoma in Norway per 
100 000 person-years by 5-year period, 1957-2016 (3). 
 
Mortality 
Worldwide it is estimated that endometrial carcinoma accounts for approximately 
76 000 deaths each year (5). Although being a common type of cancer, prognosis is 
usually good and mortality rates are low. In 2015 there were 67 deaths due to 
endometrial carcinoma in Norway. Survival is highly dependent on disease stage, and 
the 5-year relative survival for endometrial carcinoma is 95.7% for patients with 
localized disease, 61% with regional disease, and 38.1% for distant metastatic 
disease. Overall, there has been a slight improvement in survival over the last decades 
(Figure 2) (3).  
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Figure 2. Five-year relative survival from endometrial carcinoma in Norway 
stratified by disease stage, 1977-2016 (3). 
 
1.1.2 Clinical aspects  
Risk factors 
Most cases of endometrial carcinoma occur spontaneously. Several factors are 
reported to associate with increased risk of developing endometrial carcinoma, 
including nulliparity, early menarche and conditions causing metabolic disturbances 
such as polycystic ovary syndrome and diabetes mellitus (1, 6, 7). For endometrioid 
endometrial carcinoma, which is the most common subtype, unopposed estrogen 
exposure is a crucial risk factor (8). Exposure to estrogen stimulates cell proliferation, 
and may cause endometrial hyperplasia, cellular atypia, and development of 
endometrial carcinoma (9). Obesity is an important risk factor, most likely due to 
enzymatic production of estrogen in adipose tissue (9, 10). The degree of overweight 
is also of significance, as an increasing body mass index leads to higher risk of 
developing endometrial carcinoma (10). The growing rate of obesity amongst women 
is believed to be the cause of more than half the endometrial carcinoma cases 
worldwide, and is expected to contribute to an increasing incidence of endometrial 
carcinoma in the future (11). In contrast, multiparity, short pre-menopausal delivery-
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free period, and long term use of oral contraceptives are factors considered to reduce 
the risk of developing endometrial carcinoma (1, 6, 7). 
 
Some hereditary disorders are associated with higher risk of developing endometrial 
carcinoma, and are believed to account for approximately 5% of cases (6, 12, 13). 
Lynch syndrome is the most common hereditary genetic predisposition, characterized 
by germline mutations in deoxyribonucleic acid (DNA) mismatch repair (MMR) 
genes which lead to increased risk of developing several cancers - including 
endometrial carcinoma and colorectal cancer. The lifetime risk of endometrial 
carcinoma in women with Lynch syndrome is 40-60% (12). Other rare hereditary 
conditions associated with higher risk for endometrial carcinoma includes Cowden 
syndrome, where patients have germline mutations in the tumor supressor gene 
Phosphatase and Tensin homolog (PTEN) (13). 
 
Clinical symptoms 
Most women are diagnosed with endometrial carcinoma after menopause, and the 
classical presenting symptom is abnormal uterine bleeding (10). Patients with 
advanced disease may also experience abdominal distention, pelvic or abdominal 
pain, or changes in bowel and/or bladder function (6). As unexpected vaginal 
bleeding urges most women to visit their doctor, the majority of patients are 
diagnosed at an early stage. Only 5-10% of patients presenting with abnormal vaginal 
bleeding actually have endometrial carcinoma, although the chance is higher with 
increasing age and presence of risk factors (10). Currently there is no evidence 
supporting screening for endometrial carcinoma in the general population, and 
screening is not believed to reduce mortality rates (10, 14).  
 
Preoperative histology 
When suspecting endometrial carcinoma, histologic evaluation of the endometrium is 
performed as part of diagnosis and pre-operative risk-stratification. Several 
procedures can be performed to obtain specimens for histological assessment, 
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including pipelle, curettage, and endometrial biopsies. An endometrial curettage is 
performed by inserting an instrument through the cervical canal and into the uterine 
cavity to scrape off the endometrium. Positive findings in pre-operative curettage are 
reported to accurately diagnose endometrial carcinoma, but a negative curettage may 
not be sufficient to rule out malignant disease (15).  If cancer is diagnosed in 
curettage specimen, determination of histological type and grade is important for risk-
evaluation and surgical planning.  
 
Histological assessment of pre-operative and hysterectomy samples is reported to be 
divergent in 10 – 33% of cases (16-22), indicating that this pre-operative evaluation is 
suboptimal as a stand-alone parameter for risk stratification and planning of 
therapeutic approach (23). Disagreement in histological classification between pre- 
and postoperative samples can be caused by several factors, including limited 
collection of tissue during pre-operative sampling, tissue in preoperative specimens 
only representing superficial areas of tumor, high degree of tumor heterogeneity, and 
poor inter-observer agreement between pathologists (20). Failure to recognize high-
risk disease from pre-operative specimens is reported to associate with poor outcome, 
most likely because patients are scheduled for less extensive surgery (16). Likewise, 
patients with pre-operative high risk and post-operative low risk classification have 
worse survival compared to those with concordant pre- and post-operative low risk 
histology. This could be due to tumor heterogeneity, and these patients may benefit 
from adjuvant treatment (22).  
 
Preoperative imaging 
Preoperative imaging is a valuable tool in planning of surgical procedures, especially 
for identification of deep myometrial invasion, cervical stroma invasion and 
evaluation of metastatic spread. However, there is no consensus on how to best apply 
imaging in order to identify high-risk cases prior to surgery, and there is a large 
variation in clinical routines both between hospitals and countries (24, 25). MRI 
and/or vaginal/transrectal ultrasound is normally recommended for local staging, 
whereas CT and/or PET are better to assess lymph node metastases and systemic 
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spread as they allow visualization of the entire pelvis, abdomen and thorax (24). 
Further information regarding the various modalities used in clinical imaging can be 
found in section 1.5. 
 
Staging, histopathologic typing and grading 
Endometrial carcinoma is a surgically staged disease, and myometrial invasion, 
metastatic spread, and lymph node involvement are assessed during the procedure. In 
2009 the International Federation of Gynecology and Obstetrics (FIGO) Committee 
on Gynecologic Oncology published their latest review on staging criteria for 
carcinoma of the vulva, cervix, and endometrium (26). Complete surgical staging 
includes sampling of pelvic and para-aortic lymph nodes, but in most hospitals this is 
not routinely performed in all patients. Table 1 describes the different stages of 

























     IA 
     IB 
 II 
   
 III 
  IIIA 
  IIIB 
  IIIC 
   IIIC1 
   IIIC2 
IV 
    IVA 
    IVB 
 
Myometrial invasion <50% 
Myometrial invasion ≥50% 
Tumor is invading the cervical stroma, but does not extend beyond the 
uterus. 
 
Tumor is invading the serosa of the corpus uteri, and/or adnexa 
Vaginal and/or parametrial involvement 
Involvement of specific lymph nodes 
Pelvic lymph nodes affected 
Para-aortic +/- pelvic lymph nodes affected 
 
Tumor invasion of the bladder and/or the bowel mucosa 
Metastases to distant locations, including intra-abdominal metastases and/or 
inguinal lymph node affection 
 
 
Endometrial tumors are also classified according to their histological appearances 
regardless of FIGO stage. Endometrioid adenocarcinoma is the most common type (≈ 
80% of endometrial carcinomas), and is characterized by the presence of endometrial 
glands with varying degree of differentiation. Endometrioid endometrial carcinomas 
are often associated with high levels of estrogen, and patients may have a history of 
endometrial hyperplasia (1, 10). Several less common types of endometrial carcinoma 
are collectively referred to as non-endometrioid tumors, with serous adenocarcinoma 
and clear cell adenocarcinomas being the most frequent. Serous adenocarcinomas are 
often characterized by a papillary architecture with poorly differentiated nuclei, while 
clear cell adenocarcinomas are characterized by the presence of clear glycogen-filled 
cells. The growth pattern of the tumor can be tubular, papillary, tubulocystic, solid or 
a mixture of these patterns (1).  
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In addition to histological type, endometrial carcinomas are also graded based on the 
amount of solid growth in the glandular parts of the tumor. Higher histological grade 
indicates less differentiation of tumor, observed as solid nests and sheets of cells 
replacing the normal glandular appearance (1). Non-endometrioid endometrial 
carcinomas are by definition considered high grade (1). Grading of endometrioid 
tumors is performed as described below, and has prognostic relevance. The majority 
of endometrioid tumors are low grade (1-2), usually associated with a favorable 
outcome if restricted to the uterus, while grade 3 endometrioid tumors are classified 
as high-risk (27).  
 
Grade 1: Less than 5% solid growth and a well-defined glandular appearance 
Grade 2: 6 - 50% solid growth and a less preserved glandular pattern 
Grade 3: More than 50% solid growth and hardly recognizable glands  
 
A major challenge in the histopathological classification of endometrial carcinomas is 
tumor heterogeneity, where different morphologic characteristics are found within the 
same tumor. The degree of heterogeneity can vary from subtle variations in cytology 
to mixed tumors with two distinctly different histological types. Tumor heterogeneity 
may have a large clinical impact, as failure to identify small populations of cells with 
aggressive features may cause wrongful assessment of prognosis and suboptimal 
treatment. Integration of molecular biomarkers may add valuable information to the 
standard histopathological evaluation, and potentially improve risk-stratification and 









Treatment recommendations for endometrial carcinoma differ between disease 
subgroups, and large variations in clinical practice exist between countries. In 
Norway the treatment of endometrial carcinoma has changed somewhat since the 
early 1980’s, favouring more extensive surgery and increased amount of lymph node 
sampling over the last period. Chemotherapy was implemented as adjuvant treatment 
during this time period, and the amount of patients receiving chemotherapy increased 
from 0% in 1981-1990 to 9% in 2001-2010. Conversely, the proportion of patients 
undergoing adjuvant radiotherapy was dramatically reduced from 75% to 12% during 
the same time period (28). 
Pre-operative risk-assessment of patients is performed in order to plan the surgical 
approach, and is based on clinical findings, histopathological evaluation of pipelle or 
curettage samples, and pre-operative imaging. The histological classification of low 
risk disease includes grade 1 and 2 endometrioid tumors with <50% myometrial 
invasion, while deeply infiltrating grade 1 and 2 endometrioid tumors, as well as 
grade 3 endometrioid tumors with <50% myometrial invasion, are referred to as 
intermediate risk. High risk endometrial carcinoma is defined as grade 3 
endometrioid adenocarcinomas with >50% myometrial infiltration as well as non-
endometrioid histology (8, 29, 30).  
 
Surgery 
The primary treatment for endometrial carcinoma is surgery, and the standard 
procedure is hysterectomy with bilateral salpingo-oophorectomy (14). For patients 
with intermediate or high-risk disease more radical surgery might be advised, 
including pelvic and para-aortic lymphadenectomy, removal of paracervical and 
parametrial structures and omentectomy (23, 29, 31). Standardized criteria for 
selection of patients to undergo lymphadenectomy have not been established, and the 
current practice varies greatly between countries (32). The clinical benefit of 
lymphadenectomy has also been debated, due to the side effects associated with the 
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procedure and the lack of agreement regarding the therapeutic value of lymph node 
removal.  However, intermediate- and high-risk patients are often routinely subjected 
to staging lymphadenectomy in order to improve post-operative risk-stratification (6, 
8, 23, 29, 31). Sentinel lymph node mapping is an intraoperative procedure, where the 
primary draining lymph nodes (which are most likely to harbor metastatic lesions) are 
identified and removed. This approach reduces the extent of surgery and long-term 
side effects compared to more extensive lymph node removal, and may represent a 
good alternative to full lymphadenectomy in patients where assessment of nodal 
status is required (33-35).  
 
Primary surgical treatment is curative in most cases, however 15-20% of patients 
experience disease relapse within few years (8, 36). Recurrent endometrial carcinoma 
is associated with a poor prognosis, especially in patients with distant metastatic 
disease (36). A key challenge in endometrial carcinoma is thus early identification of 
patients that are likely to suffer a relapse, in order to consider adjuvant treatment.  
 
Adjuvant therapy 
Adjuvant therapy is considered for patients with intermediate or high-risk disease to 
eliminate disseminated cancer cells or potential residual disease after primary 
surgery. Traditionally, hormonal treatment, radiation treatment and chemotherapy 
have been the available alternatives, while immunotherapy and targeted therapies 
recently have emerged as new cancer treatment strategies (37).    
 
Hormonal treatment can be applied as adjuvant treatment in endometrial carcinoma 
patients who are ineligible for chemotherapy (38). Several substances are available 
(including tamoxifen and aromatase inhibitors), but the most commonly used are 
progestins. Use of hormonal therapy as single agent or combinational therapy has not 
been found to improve survival in women with advanced or recurrent endometrial 
carcinoma (39). However; checking the hormone receptor status of patients prior to 
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applying hormonal treatment is not standard procedure in all hospitals, and this may 
partially explain the lack of survival benefits. 
 
Radiation treatment consists of local ionizing radiation applied directly at the tumor, 
and can be performed as vaginal brachytherapy or external beam radiotherapy 
(EBRT). Vaginal brachytherapy is reported to be effective in preventing local 
recurrence, and is associated with fewer side-effects than EBRT (40). No survival 
benefit has been found from treating endometrial carcinoma patients with adjuvant 
radiotherapy, although radiation is found to reduce locoregional recurrence. Radiation 
treatment is thus not recommended for low-risk endometrial carcinoma, but may be 
considered in intermediate- and high risk cases (41-44).  
 
Conventional chemotherapeutics are systemically administered drugs that target 
rapidly dividing cells by interfering with one or more phases in the cell cycle, 
potentially eliminating residual cancer cells. Unfortunately, these drugs also exert 
cytotoxic effects on cells with a natural high turnover (epithelial cells, bone marrow 
cells, etc.), causing side effects such as hair loss, diarrhea, nausea and 
immunodepression which can be damaging to elderly and co-morbid patients (37). 
Response rates of chemotherapeutic treatment in endometrial carcinoma are usually 
modest, with short progression-free intervals of 4-6 months. The effect on survival is 
also limited, with median overall survival of 7 to 12 months (38). Anthracyclines, 
platinum compounds and taxanes are amongst the most heavily used drugs in 
endometrial carcinoma, with relatively poor response rates. Better response is 
observed with use of combined chemotherapeutic drugs than single agents alone (38). 
Commonly applied first-line adjuvant chemotherapeutic regimens include paclitaxel 
and carboplatin (14, 32), however the most optimal regimen has not yet been defined 
(45).  
 
Genetic characterization of tumors has revealed several cancer-specific molecular 
pathways that potentially can be targeted through adjuvant treatment. As targeted 
therapies intervene with specific molecular mechanisms in cancer cells it is believed 
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that this approach may be more efficient than traditional drugs, while simultaneously 
reducing the damaging effect on normal tissue (38). The most common types of 
targeted therapies are small molecule inhibitors and monoclonal antibodies. Several 
of these drugs have been approved for clinical use, including bevacizumab for 
treatment of colorectal cancer and non-small cell lung cancer (46-48), temsirolimus 
for advanced renal cell carcinoma (49) and trastuzumab for human epidermal growth 
factor 2 (HER2) positive breast cancer (37). Currently there are no targeted therapies 
specifically approved for endometrial carcinoma (8, 50) but several candidates have 
been and are being explored in clinical trials, including phosphatidylinositol-4,5-
biphosphate 3-kinase (PI3K)- and mammalian target of rapamycin (mTOR) inhibitors 
(51).  
 
The ability of cells to avoid destruction by the immune system is important for 
formation of tumors, and is considered an emerging hallmark of cancer (52). Several 
clinical trials evaluating immunotherapeutic drugs in patients diagnosed with 
endometrial carcinoma are ongoing, including studies of the immune checkpoint 
inhibitor pembrolizumab (NCT02549209, NCT02630823, NCT02054806 (53)). 
Pembrolizumab was recently approved by the United States Food and Drug 
Administration for use in solid tumors with MMR deficiencies, and may thus be used 











1.1.4 Personalized medicine 
Cancer has traditionally been treated with standardized protocols for all patients with 
similar diagnosis, a “one size fits all” approach which takes little consideration of 
disease heterogeneity and individual variations. Personalized oncology aims to select 
optimal therapeutic and preventive protocols for individual patients based on their 
specific molecular and genetic sequence variants – the right treatment for the right 
patient at the right time. However, in order to incorporate these principles into clinical 
practice it is necessary to identify specific biomarkers for disease characterization and 
for tailoring targeted therapies.  
 
1.2 Cancer genetics and signaling pathways 
1.2.1 Genetic alterations 
Cancer is a genomic disease where changes in gene expression caused by molecular 
events such as mutations, gene amplifications, chromosomal rearrangements etc. may 
alter the genetic landscape of a cell. Tumor development is a dynamic, multistep 
process that is largely shaped by underlying mechanisms such as genomic instability. 
The genetic heterogeneity that follows is favourable for cancer evolution as it 
increases the chance that premalignant cells become malignant, and that some cancer 
cell clones survive the selection pressure in the microenvironment (52, 55). 
Heterogeneity exists between subclones of cells within a specific tumor (intratumor 
heterogeneity), but also between similar tumors from different patients as well as 
between different types of tumors (intertumor heterogeneity) (56). Additionally, as 
most tumors are capable of continuous evolution, the genetic landscape of metastatic 
lesions does not necessarily equal that of the primary tumor. Heterogeneity represents 
a major challenge for diagnosis, therapy and for development of new drugs, and 
longitudinal sampling and multiple sampling sites may thus be vital in order to better 
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understand the biology of tumors - including drug sensitivity and development of 
therapeutic resistance (57).  
 
Several genomic cancer platforms (including The Cancer Genome Atlas (TCGA)) 
have been established in order to reveal the genetic landscape of different tumor 
types. In addition to profiling genetic aberrations in specific cancers, efforts are made 
to compare data from different cancer types in pan-cancer projects (58). Genomic 
analyses have revealed that some genes, including Tumor protein 53 (TP53), PTEN 
and Phosphatidylinositol-4,5 biphosphate 3 kinase catalytic subunit alpha (PIK3CA), 
are commonly mutated in several tumor types, whereas others are specific for single 
cancers (59). Endometrial carcinoma has been classified into four distinct subgroups 
by the TCGA research network based on their genetic characteristics; Polymerase ε 
(POLE) ultramutated, microsatellite instability (MSI) hypermutated, copy number 
high, and copy number low (Table 2) (60). As the individual subgroups are associated 
with differences in survival and may be linked to treatment response, molecular 
subtyping should be considered in endometrial carcinoma patients. However, 
extensive genetic analyses are expensive and identification of surrogate markers (i.e 
mutS homolog 6 (MSH6) and mismatch repair endonuclease PMS2 (PMS2) for 
identification of patients with MMR deficiencies in the MSI subgroup) may facilitate 

















POLE - Very high number of mutations 
- Favorable PFS 
- Frequent mutations in PTEN, PIK3CA and KRAS 
MSI - High degree of mutations 
- Frequent MLH1 promoter methylation 
- Low number of SCNAs 
- Few mutations in TP53 
Copy number high - High number of SCNAs 
- Frequent TP53 mutations 
- Low degree of MSI 
- Poor PFS 
Copy number low - Low mutation rate 
- Microsatellite stable 
KRAS proto-oncogene (KRAS), MutL homolog 1 (MLH1), Microsatellite instability 
(MSI), Progression-free survival (PFS), Phosphatidylinositol-4,5 bisphosphate 3-
kinase catalytic subunit alpha (PIK3CA), Polymerase ε (POLE), Phosphatase and 
Tensin homolog (PTEN), Somatic copy number alterations (SCNA), Tumor protein 
p53 (TP53) 
 
1.2.2 Signaling pathways  
Cells can receive several types of stimuli through direct contact with neighbouring 
cells, from local mediators (paracrine signaling), hormones (endocrine signaling), or 
by self-stimulation (autocrine signaling). Activation of various extra- or intracellular 
receptors generates a non-linear signaling cascade that ultimately may affect several 
cellular processes, including proliferation, growth, metabolism and apoptosis (52, 
55). Highly controlled transmission of signals is essential for normal cell function and 
for cells to respond appropriately to specific stimuli. Signaling pathway aberrations 
contribute to several of the “hallmarks of cancer” including self-sufficiency in growth 
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signals and insensitivity to anti-growth signals (52, 55). A variety of signaling routes 
are known to be dysregulated in cancer, including the PI3K/Protein kinase B 
(AKT)/mTOR pathway. When activated, this pathway leads to an increase in cell 
growth, protein synthesis and angiogenesis as well as inhibition of apoptosis (63). 
The tumor suppressor protein PTEN is a negative regulator of the PI3K/AKT/mTOR 
pathway. As a high number of patients with endometrial carcinoma (particularly 
endometrioid) have lost expression of PTEN, the PI3K/AKT/mTOR cascade is 
amongst the most commonly dysregulated signaling pathway in this type of cancer 
(54, 63). Other known signaling aberrations in endometrial carcinoma include 
overexpression of HER2 and dysregulation of the RAS/RAF/mitogen-activated 
protein kinase kinase (MEK) pathway (54, 63, 64). 
1.3 Biomarkers 
A biomarker is often defined as  “a characteristic that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” (65). Using biomarkers to 
identify high-risk disease and stratify patients to specific treatments may improve 
response rates and survival for a large number of cancer victims (8). However, the 
translation process from bench to bedside is both long and cumbersome, and only a 
limited number of biomarkers have been successfully implemented into clinical 
practice (66, 67). This is also the case in endometrial carcinoma  (68).   
  
Prognostic biomarkers 
A prognostic biomarker predicts the natural course of disease, distinguishing tumors 
associated with a good outcome from those with a poor outcome irrespective of 
treatment. Although prognostic biomarkers are unable to predict the response to a 
specific therapy, they can be useful to identify high-risk patients that, in general, 
might benefit from more aggressive treatment (66, 69). Prognostic biomarkers may 
reduce overtreatment of patients with low-risk tumors who do not have added benefit 
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from extensive treatment, and also under-treatment of patients who otherwise would 
receive only standard care (66). Examples of prognostic biomarkers currently used in 
clinical diagnosis of cancer includes prostate-specific antigen (PSA) levels in serum 
of patients with prostate cancer and elevated serum CA125 level in ovarian cancer 
(70, 71). Although lagging behind other cancer types when it comes to clinical 
implementation of biomarkers, several prognostic markers have been rigorously 
investigated in endometrial carcinoma, including p53 (72), DNA ploidy (73-75), and 
the hormone receptors estrogen receptor α (ERα) (76-78) and progesterone receptor 
(PR) (78, 79). Additionally, new, potential prognostic markers such as L1 cell 
adhesion molecule (L1CAM) (80-84) are emerging.  
 
Predictive biomarkers 
Predictive biomarkers forecast the likely response to a specific therapeutic 
intervention. Such markers can be used to select which patients should receive a  
particular drug, or they can be applied in early stages of therapy to predict therapeutic 
response (69). Predictive biomarkers are implemented in several cancer types, 
including HER2 overexpression for allocation of trastuzumab in breast cancer, 
presence of the fusion gene BCR-ABL for assigning imatinib treatment in chronic 
myeloid leukaemia and KRAS mutational status for selecting patients eligible for 
epidermal growth factor receptor (EGFR) targeting drugs in colorectal cancer (70, 
85).  No biomarkers are currently clinically applied to predict the response to specific 
treatments in endometrial carcinoma, and identifying markers that can select the right 
patients and monitor their response would potentially increase the response rates of 
both new and existing drugs (86). Candidate markers include mutated PTEN for 





Imaging biomarkers can be used for non-invasive monitoring of tumors to provide 
both anatomical and functional information, and can also be used to evaluate 
treatment response (69). Several imaging parameters have been reported as potential 
preoperative biomarkers in endometrial carcinoma, including tumor size, ultrasound 
echogenicity and vascularization, functional MRI parameters (i.e. apparent diffusion 
coefficient (ADC) -value and blood flow) and metabolic PET/CT parameters such as 
metabolic tumor volume (MTV) and total lesion glycolysis (TLG) (25, 87-90). 
 
1.4 Preclinical cancer models 
Preclinical research is a wide term, including a variety of techniques and model 
systems that can be applied to study specific hypotheses prior to testing in clinical 
trials. The development of cancer models is a dynamic process, involving a series of 
steps where the model system is defined, generated and improved based on the 
outcome of initial testing (91). The most common preclinical research systems are in 
vitro and in vivo models, where specific events are studied in laboratory- or animal 
studies. Computational in silico models are also of increasing interest, and can be 
used to generate predictions and hypotheses. There are many advantages with a 
computational approach, including low costs, high accuracy, and rapid estimation of 
specific interventions on a range of different parameters. Still, these model systems 
are developed from pre-existing data which often have been generated through 
multiple experiments and under different conditions (92). Hypotheses must therefore 




1.4.1 In vitro models 
In vitro experiments are typically performed in test tubes or cell cultures, and have 
been important model systems in preclinical cancer research for decades. Major 
advantages of in vitro models are that they provide a controlled system that is feasible 
for studies of molecular mechanisms, they are cheap and data can be acquired rapidly. 
However, there are several limitations. Cell cultures are often criticized for lacking 
stromal interactions, accumulating mutations, adapting to in vitro conditions, and 
failing to recapitulate the heterogeneity found in tumors in vivo (93, 94). 
Additionally, performing studies on single cell lines may lead to wrongful 
interpretation of data, as the response in individual cell lines could represent only a 
subgroup of tumors (or a subpopulation of cells within a tumor) and not the entire 
patient population. High-throughput screening of multiple cell lines may thus 
improve the comparability of results in in vitro experiments and clinical trials (94). 
Still, prior to clinical testing hypotheses generated from in vitro experiments should 
be validated in in vivo preclinical models. 
 
1.4.2 In vivo models  
Animal models are commonly used to generate hypotheses and perform initial studies 
before proceeding to testing in human patients. Compared to in vitro models, animal 
models provide a more natural environment for tumor establishment and disease 
evolvement. Cells grown in vivo are able to interact with normal tissue cells and 
components, and to undergo disease related events such as invasion, migration and 
dissemination. Additionally, many molecular and physiologic processes are similar in 
animals and humans (95). Animal models are amongst the best currently available 
systems for studies of human cancer. Still, results from preclinical experiments are 
often not reproducible in subsequent clinical trials (86, 96). It is thus important to 
establish clinically relevant animal models to explore the mechanisms of 
development, progression, invasion and metastasis of cancer in a systemic setting, 
and for preclinical studies of biomarkers and therapeutic response (97, 98). 
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1.4.3 Mouse models 
The use of laboratory mice has a long tradition in medical research. Mice are small of 
size, easy to breed and have a short life-span, which makes them easy and relatively 
cheap to house, feed and handle (95, 99). In addition there is a high degree of 
similarities between the human and mouse genome which improves their suitability 
as model animals for human disease. Many different mouse models exist; however, 
not all models are equally applicable for all types of preclinical studies. Genetically 
engineered models (GEM) can be used to study genomic mutations in a systemic 
setting, and mutations that cause tumor development can be induced in germline cells 
by embryonic engineering or be selectively expressed in specific cells and tissues (95, 
99-101). Isograft models are established by transplantation of cells or tissue between 
animals with the same genetic background, so there is no need to compromise the 
host immune system to enable tumor engraftment. Although a vast number of 
mechanisms involved in cancer establishment and progression can be studied using 
GEM and isografts, both tumor and stromal cells are of mouse origin - making them 
less optimal models for human tumor biology (99). Xenograft models are generated 
by transplantation of cells or tissue between individuals of different species, and thus 
allows for human material to grow in a murine host. Due to the human origin of 
xenografts, these models may be more representative of human cancer than GEMs 
and isografts. 
 
The most commonly used xenograft models are derived from immortalized human 
cancer cell lines. However, long time culturing of cell lines in vitro may alter their 
genetic and functional characteristics, making cell line based mouse models less 
representative of clinical disease (86). PDX models are established by implantation of 
cell suspension or small pieces of tissue from a patient biopsy, and are believed to 
mimic human clinical cancer more closely than cell line based models because 
molecular and histologic characteristics of the human tumor are better preserved (86, 
97, 102, 103). In spite of their advantages, PDX models are still not very widely used. 
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They are often time-consuming to establish (causing housing and keeping of PDX-
models to be more costly), and requires more time spent on handling and observation 
compared to several other available preclinical models (103). Not all primary cells 
form tumors in mice, and cells that engraft may harbour more aggressive features 
than the cells that do not. PDX models have been generated for a variety of cancers, 
including breast, colorectal and renal cell cancer (86). It has been demonstrated that 
drug response (including both standard chemotherapeutic and targeted treatments) in 
PDX models is similar to the response in the corresponding human donor (86, 104), 
suggesting that the use of PDX models may improve the translational value between 
preclinical studies and clinical trials. Several mouse models of endometrial carcinoma 
have been generated (97, 105-110), including PDXs (111-113). In addition to primary 
tumors, endometrial carcinoma xenografts have also been established from both 
metastatic and recurrent lesions (111). 
 
Xenograft models can be generated through implantation of tumor cells under the 
skin (subcutaneously) or in the organ of origin (orthotopically). The subcutaneous 
method is commonly applied as it is low cost, little time consuming, does not require 
surgical training, and tumor development is easy to monitor and measure (98, 102). 
Still, subcutaneous tumors are surrounded by a completely different 
microenvironment than the organ they usually would inhabit, and are not necessarily 
representative for tumors in the primary site. Tumors grown in such models will often 
lack infiltrative behavior, are less likely to metastasize, and may respond completely 
different to chemotherapy than tumors found in their original milieu (97, 98, 105, 
114). In orthotopic models cancer cells are allowed to grow and metastasize under 
conditions more similar to those of the primary tumor, making it a more clinically 
relevant model (98, 102, 105, 114).  However, generation of orthotopic models often 
requires surgical expertise, and monitoring of tumor development is more challenging 
in orthotopic compared to subcutaneous models (86, 98, 115). The latter problem can 
be overcome through use of in vivo imaging. 
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1.5 Advanced imaging modalities 
Imaging can be used for non-invasive collection of information on the anatomy and 
physiology of tumors, and is applied in the diagnosis and follow-up of multiple 
cancer types; including gynaecological cancers. Although several hospitals have 
included imaging as part of the preoperative diagnostic work-up in endometrial 
carcinoma there is little agreement on when and how to use these imaging techniques, 
and different institutions and countries have varying practices (24, 25).  Imaging of 
preclinical cancer models is also of great importance; especially as such models are 
becoming continuously more complex. The most common imaging alternatives 
available for clinical and preclinical purposes will be presented over the next sections, 
with a particular focus on imaging modalities relevant for endometrial carcinoma. 
Strengths and weaknesses of different imaging modalities are summarized in Table 3. 
 
Table 3. Strengths and limitations of selected imaging modalities 
Modality Strengths Limitations 
US (116) - Inexpensive 
- Fast 
- Doppler visualizes blood 
flow 
- Accurate measurement of 
tumor size 
- Operator variability 
- Unsuited for brain and 
bone tumors 
- Difficult to detect 
metastatic disease 
MRI (116, 117) - High spatial resolution 
- Excellent soft tissue 
contrast 




- No radiation 
- Long acquisition time 
- High equipment costs 
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CT (116) - High contrast 
- Good anatomical 
visualization 
- Poor soft tissue contrast 
- Radiation 
PET (116-118) - High sensitivity, 
irrespective of depth 
- Functional imaging 
- Several available tracers 
- High demands to facilities 
- Radiation 
- Expensive 
- Low spatial resolution 
- Little anatomical 
information 
BLI* (116, 119, 
120) 
- Cost efficient 
- High throughput 
- High signal-to-noise ratio 
- Requires reporter genes 
- No anatomical information 
- Semi-quantitative 
NIRF* (121) - Reporter genes not 
required 
- High throughput 
- Targeted fluorophore 
probes 
- Tissue autofluorescence 
- Low signal-to-noise ratio 
- Limited penetration of 
tissue (≈ 1 cm) 
Bioluminescent imaging (BLI), Computed tomography (CT), Dynamic contrast 
enhanced (DCE), Magnetic resonance imaging (MRI), Near-infrared fluorescent 




Transvaginal ultrasound is commonly used in the initial diagnosis of endometrial 
carcinoma (24, 25). In ultrasound, sound waves over 20 MHz are generated by a 
transducer and directed towards the tumor and surrounding tissue. When hitting 
borders between tissues with different acoustic impedance, sound waves are reflected 
and the echo is used to generate a grayscale image (116). There are several 
advantages with ultrasound as it is a rapid, low-cost and minimally invasive 
procedure. Challenges include interobserver variation, poor image quality in obese 
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patients due to excess amounts of fatty tissue and difficulties in evaluation of 
disseminated disease. To the best of the author’s knowledge, ultrasound has so far not 
been used to evaluate endometrial carcinoma in preclinical models.  
 
Magnetic resonance imaging 
MRI machines use superconducting magnets to generate a constant external magnetic 
field that affects the alignment of protons in the patient body. Radiofrequent pulses 
are turned on and off to interfere with the protons, and this activity results in an 
alternating electrical current that can be registered as an MR-signal. MRI is highly 
feasible for visualization of soft tissue, offering high resolution and excellent contrast 
in fat rich and water rich tissues (122). The main limitations of the MRI technique are 
that patients with metal implants or electronic medical implants (i.e. pacemakers) 
cannot be scanned due to the strong magnetic field, that scan-time is relatively long, 
and that the instrumentation is costly and requires high technical expertise (122). In 
endometrial carcinoma MRI is often considered to be the preferred pre-operative 
imaging method, and is performed to assess the depth of myometrial infiltration and 
invasion of cervical stroma (123). Standard MRI can also be used to estimate tumor 
size and to identify suspicious lymph nodes (123, 124). Paramagnetic substances (i.e. 
gadolinium) can be injected intravenously to enhance contrast (122), and is used to 
better delineate the tumor from the myometrium in endometrial carcinoma patients 
(24). Functional MRI techniques are increasingly explored, and may add valuable 
information regarding the physiological properties of a tumor. Dynamic contrast 
enhanced (DCE) MRI enables characterization of tumor microvasculature (123, 124), 
while diffusion weighted images (DWI) visualizes differences in tissue water 
diffusion as a measure of tissue cellularity which can be used to differentiate tumor 
from normal tissue (123). DCE-MRI and DWI parameters (low blood flow, low 
ADC-values, etc.) are reported to associate with features of aggressive endometrial 
carcinoma and reduced survival, and may serve as potential imaging biomarkers 
(125).  The ability of MRI to detect tumor in preclinical models has been 
demonstrated in several cancers, including non-small-cell lung cancer (126). As far as 
 43 
the author is aware, MRI has not previously been used for tumor imaging in 
endometrial carcinoma xenograft models. 
 
Computed tomography 
CT is an imaging technique using several narrow x-ray beams, which can be 
reconstructed into a three-dimensional image of patient anatomy (127). Images are 
created based on differences in x-ray absorption, illustrating different tissues by 
various shades of grey. Advantages of CT-technology include that it is relatively 
quick to acquire images compared to other modalities, it is applicable for most body 
systems, and it provides more details in deep tissues that may be less accessible by 
e.g. transabdominal ultrasound. CT also offers high resolution in tissues with good 
contrast, such as bone and lungs. The main disadvantages are that patients are 
exposed to radiation, and that intrinsic contrast in soft tissue is limited (116). CT is 
not commonly utilized as a single imaging modality in endometrial carcinoma due to 
poor diagnostic performance for local staging. However, CT is widely used to assess 
lymph node metastases or distant spread, either alone or combined with PET imaging 
allowing for attenuation correction and anatomical correlation in both clinical and 
preclinical applications.  
 
Positron emission tomography 
PET imaging is based on intravenous injection of short-lived radionuclides linked to 
biologically active elements, and the physiological information from the PET-scan 
can be combined with the anatomical information from CT or MRI-scans to create a 
fusion image (128, 129). PET may also be a valuable tool for assessment of adjuvant 
treatment effects, as metabolic changes in tumor tissue may be evident at an earlier 
stage than alterations in tumor volume (118, 129-131). However, PET images may be 
affected by factors such as signal spilling, non-tumor activity (i.e. signal from urinary 
system or intestine) and scanner properties that potentially may lead to over-or 
underestimation of tumor size and metabolic activity (131). Additionally, PET 
imaging is expensive, exposes the patient to radiation, and poses high demands to 
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facilities and staff. Several PET-tracers exist, each with specialized properties which 
make them feasible for different types of investigations. One of the most commonly 
used PET-tracers is 18F- FDG. 18F-FDG is imported into cells by glucose transporting 
molecules and phosphorylated by hexokinase, thereby trapping it inside the cell 
(118). High glucose uptake is a common feature of cancer cells, which makes 18F-
FDG a feasible tracer for both qualitative and quantitative measures. Another 
available PET-tracer is 18F- FLT. 18F- FLT enters the cell by both passive diffusion 
and active nucleoside transporters, and gets trapped intracellularly after being 
phosphorylated by thymidine kinase 1 during cell cycle S-phase (132). 18F- FLT PET 
takes advantage of the increased cell proliferation that is characteristic of many 
cancers. Several molecular parameters can be evaluated based on PET scans to 
elucidate inherent properties of the tumor. Standard uptake value (SUV) is the 
measured activity in tissue divided by injected activity per unit body weight, and 
describes the uptake of tracer in tumor. Measures of metabolic tumor burden includes 
MTV and TLG (133). In endometrial carcinoma, PET/CT imaging using 18F-FDG as 
tracer is reported to be a valuable tool both for detection of metastatic lymph nodes 
prior to surgery and for identification of recurrent disease (134). PET/CT may also be 
used in preclinical applications, and has been successfully employed in studies of 
lung cancer and melanoma models (135, 136) . However, there are no previous 
reports of PET/CT imaging of endometrial carcinoma models.  
 
Optical molecular imaging 
OMI is applicable for real-time visualization of tumor growth and metastasis, as well 
as observation of treatment effects in vivo (121, 137). The technique is non-invasive, 
does not require radiant substances, is relatively low cost and the equipment is easy to 
operate. However, there are also some disadvantages with OMI. Due to the poor 
penetration of photons in tissue there is a depth restriction which makes it less 
applicable in deep viscera. Spatial resolution is low due to the amount of light 
scattering in biological tissue (121), and the anatomy is difficult to comprehend. One 
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OMI modality commonly used for research purposes is BLI. The firefly luciferase 
enzyme catalyzes the transformation of D-luciferin to oxyluciferin in the presence of 
O2, Mg
2+, and adenosine triphosphate, yielding the emission of light as well as 
byproducts such as adenosine monophosphate, CO2, and pyrophosphate (138, 139). 
BLI is a high-throughput technique that is relatively easy to conduct. As normal 
mammalian cells do not express luciferase, BLI offers a high signal-to-noise ratio and 
excellent sensitivity (120, 121). The major limitation is that cells need to be 
transfected with a luciferase expressing vector for BLI to be eligible (139), and this 
imaging technique is thus not applicable for clinical use. However, BLI has been 
demonstrated as a valuable tool for visualization of luciferase positive tumor cells in 
several cancer models, including endometrial carcinoma (97, 107, 110). 
Another OMI modality that is feasible for in vivo studies is NIRF. Fluorescent 
molecules are excited by light of specific wavelengths, and emit light with a different 
wavelength when returning to their ground state (137, 139, 140). NIRF is not visible 
to the human eye, and highly sensitive cameras or detectors are needed to register the 
emitted light. Fluorescent in vivo imaging can be challenging due to high degree of 
tissue autofluorescence and low signal-to-background ratios (121). Photons can be 
scattered or absorbed by surrounding tissue, reducing the amount of signal that is 
received by the detector. Light with wavelengths above 1100 nm will be almost 
completely absorbed by water (which is abundant in most tissue), while light with 
wavelengths in the range of 400-500 nm will be absorbed by molecules such as 
hemoglobin and melanin. By using fluorescent molecules that emit light in the near-
infrared range (700-900 nm) some of these challenges can be overcome, as infrared 
light is less absorbed and enables better tissue penetration (121, 139-141). Although 
there is currently little tradition for using optical imaging in clinical settings, image-
guided surgery using fluorescent dyes (i.e. indocyanine green) is now being explored 
and represents a promising tool for detection of sentinel lymph nodes in several 
gynecological cancers – including endometrial carcinoma (142). NIRF imaging has 
been demonstrated to visualize tumor in preclinical models of several cancers, 
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including acute myeloid leukemia (AML) and epithelial ovarian cancer (143, 144). 
NIRF imaging of endometrial cancer mouse models has not yet been reported.  
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2. Aims of the project 
2.1 Background 
Endometrial carcinoma is the most common pelvic gynaecologic malignancy, and the 
incidence is expected to increase in the future due to an ageing and more obese 
population. Prognosis is good for most patients, but for those who experience 
recurrent disease the outcome is often poor. There is a need for identification and 
validation of new biomarkers for endometrial carcinoma, both to improve risk-
stratification and to tailor treatment for individual patients. Establishment of robust 
and clinically relevant preclinical models is essential in order to increase the 
translational success rate from preclinical research to clinical trials. Implementation 
of non-invasive small animal imaging techniques is also vital, as these methods allow 
continuous monitoring of disease development and response to treatment in vivo.  
 
2.2 Overall aim 
The overall aim of this project was to explore potential biomarkers in endometrial 
carcinoma, and to develop relevant preclinical model systems that may be used for 
studies of new biomarkers and anti-cancer therapies. 
 
2.3 Specific aims 
Paper I: The aim of this study was to establish cell line based and patient derived 
orthotopic mouse models of endometrial carcinoma, and to evaluate the feasibility of 
selected small animal imaging modalities with regards to monitoring of tumor growth 
and metastatic spread. 
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Paper II: We aimed to develop an NIRF imaging protocol that can be used for 
longitudinal monitoring of tumor growth and treatment response in orthotopic 
endometrial carcinoma PDX models. 
 
Paper III: The aim of this study was to validate ASRGL1 as a postoperative 
prognostic biomarker in endometrial carcinoma, and to explore the expression of 
ASRGL1 in precursor lesions, primary tumors and metastases. 
 
Paper IV: We aimed to evaluate the ability of ASRGL1 protein expression in 
preoperative samples to identify endometrial carcinoma patients with high risk of 
aggressive disease and poor survival prior to surgery. 
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3. Material and methodological conciderations 
3.1 Patients and clinical samples 
3.1.1 Patient series 
Patients treated for endometrial carcinoma at HUS were prospectively included 
between March 2001 and October 2015. HUS is the referral hospital for Hordaland 
County, covering approximately 10% of the Norwegian population. The HUS cohort 
is regarded a population-based patient series as both incidence rates, patient- and 
disease characteristics for this region are representative compared to the entire 
population in Norway (3). In addition to the patients collected at HUS, nine other 
hospitals in Norway, Sweden and Belgium have contributed with samples and data 
from prospectively included endometrial carcinoma patients in the Molecular 
Markers in Treatment of Endometrial Cancer study (MoMaTEC, NCT0059884). All 
patients have given written informed consent prior to inclusion, and biological 
samples, clinicopathological information and follow-up data have been collected at 
the respective centres. The biobank contains tissue samples from preoperative 
curettage, hysterectomy specimens, and metastatic lesions, and tissue samples were 
snap-frozen in liquid nitrogen and/or fixed in formalin. Clinicopathological 
information including age, histological type, histological grade and follow-up data 
was retrieved from medical records. A series of patients diagnosed with CAH has 
also been collected and clinical information retrieved as for endometrial carcinoma 
patients. As surgical treatment of CAH is presumed to be curative, these patients have 
no follow-up data. An overview of biological samples and applied methods is shown 
in Figure 3. 
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Figure 3. Overview of patient samples and methods used in papers II- IV. Numbers 
in bars represent included patients for each analysis. Dark purple: curettage samples 
from patients treated at Haukeland University Hospital. Light purple: curettage 
samples from patients treated at other hospitals. Abbreviations: complex atypical 
hyperplasia (CAH), immunohistochemistry (IHC), magnetic resonance imaging 
(MRI), positron emission tomography/computed tomography (PET/CT).  
 
3.1.2 Tissue microarrays 
Formalin fixed paraffin embedded (FFPE) tissue was used to generate tissue 
microarrays (TMA). The area with the highest tumor cell content was identified on 
hematoxylin and eosin stained slides by an experienced gynecologic oncologist, and a 
custom made precision instrument (Beecher instruments, Silver Spring, MD, USA) 
was used to punch out tissue cylinders (0.6 mm) from the donor block before 
mounting in a recipient paraffin block (145). Three tissue cylinders were collected 
from CAHs, curettage specimens and primary tumors, and one tissue cylinder from 
metastatic lesions. For patients treated at other centers than HUS, only tissue from 




In this project we used IHC to evaluate protein expression in FFPE tissue collected 
from endometrial carcinoma patients and xenograft models. With the exception of 
ASRGL1 staining, which was performed by automated IHC using a LabVision 
Autostainer 480S (Thermo Fisher Scientific, Runcorn, UK), all immunohistochemical 
staining was performed at our facility using a standardized protocol. Tissue sections 
were dewaxed in xylene and rehydrated in graded ethanol series prior to microwave 
boiling for 15 minutes in target retrieval buffer (Tris EDTA – pH 9 or Citrate – pH 6). 
Slides were covered with peroxidase block for 8 minutes before application of 
primary antibody. Specifications for the different primary antibodies are listed in 
Table 4. For all antibodies a secondary horse radish peroxidase conjugated agent 
(anti-mouse or anti-rabbit) was added for 30 minutes and diaminobenzidine applied 



















Table 4: Antibodies used for immunohistochemistry 
Target Primary antibody Buffer Dilution Incubation 
ASRGL1 HPA029725 (146, 147)   
Atlas antibodies, Sweden 
 
AMAb90907 




















1:200 60 min 
ERα HC-20* 




1:400 60 min 
 
SP-1* 












1:50 30 min 





1:150 30 min 
*Used to stain tissue samples from mice xenografted with human endometrial 
carcinoma cells.  Asparaginase-like protein 1 (ASRGL1), Cell signalling technology 
(CST), Epithelial cell adhesion molecule (EpCAM), Estrogen receptor alpha (ERα), 
Ethylenediaminetetraacetic acid (EDTA),  Progesterone receptor (PR) 
 
IHC staining of slides was assessed by standard light microscopy, evaluating the 
staining of epithelial tumor cells. For each patient a staining index (SI) was calculated 
by multiplying staining intensity (0-3) and area of positive stained tumor cells (1 = < 
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10%, 2 = 10 – 50%, 3 = > 50%). Cases were ranked based on SI for statistical 
analyses, and categorized into tertile/quartile groups according to frequency 
distribution and subgroup size. Groups with similar survival were combined. Table 5 
lists the cut-offs for IHC biomarkers included in this project.  
 
Table 5: Biomarker cut-off, immunohistochemistry 
 SI defined as loss/low 
expression 
SI defined as high 
expression 
ASRGL1 0 – 1 2 – 9 
EpCAM 0 – 4  6 – 9  
ERα 0 – 3 4 – 9 
PR 0 1 – 9 
Asparaginase-like protein 1 (ASRGL1), Epithelial cell adhesion molecule (EpCAM), 
Estrogen receptor alpha (ERα), Progesterone receptor (PR), Staining index (SI) 
 
 
3.1.4 Ribonucleic acid (RNA) microarray analysis 
Tissue samples were collected during surgery, snap-frozen in liquid nitrogen and 
stored at -80°C. Hematoxylin and eosin stained slides were used to identify areas with 
high tumor cell content (preferably > 80%, minimum 50% tumor purity). Extraction 
of RNA was performed using the RNeasy Mini Kit (Qiagen, Hilden, Germany). The 
quality of RNA extracts was assessed using a Nanodrop 1000 spectrophotometer 
(Thermo Scientific, Waltham, MA, USA) and an Agilent 2100 Bioanalyzer (Agilent, 
Santa Clara, CA, USA).  Samples were hybridized to Agilent Whole Human Genome 
Microarrays 44k according to the manufacturers’ instructions, and subsequently 
scanned by the Agilent Microarray Scanner Bundle. Log 2 transformation and 
quantile normalization of data was performed. Expression data was analysed using 
the J-Express software (Molmine, Bergen, Norway). In paper III patients were 
ranked by ASRGL1 mRNA expression and grouped in quartiles. The lowest quartile 




This study has been approved according to Norwegian legislation, including the 
Norwegian Data Inspectorate, Norwegian Social Sciences Data Services and Western 
Regional Committee for Medical and Health Research Ethics (REK 2009/2315, REK 
2014/1907, REK 2018/594). 
 
3.2 Pre-operative imaging 
Preoperative MRI and 18F-FDG PET/CT have been routinely performed in 
endometrial carcinoma patients treated at HUS since 2009 and 2011, respectively. In 
paper IV selected MRI and 18F-FDG PET parameters were related to ASRGL1 
expression in pre-operative curettage.  
 
3.2.1 Magnetic resonance imaging 
MRI of patients was performed according to a standardized protocol, using a whole-
body 1.5-T MRI system (Siemens Avanto running Syngo v. B17, Erlangen, 
Germany) with a six-channel body coil (149, 150). The largest tumor diameter was 
identified and measured in three planes (a, b, c). Tumor volume was estimated as 
following: Tumor volume = (a x b x c)/2 (151). T1-weighted images were acquired 
before and after intravenous injection of contrast (Dotarem, Guerbet, 0.1 mmol 
gadolinium/kg bodyweight). DWI of the pelvis was performed by an axial two-
dimensional echo planar imaging sequence with b-values of 0 and 1000 s/mm2, and 
used for generation of ADC-maps. DCE-MRI was acquired with 12 axial slices and a 
temporal resolution of 2.5 s Blood flow and transfer constant from extravascular 
extracellular space to blood were calculated using the extended Tofts kinetic model 
with a standardized arterial input function (125) 
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3.2.2 PET/CT imaging 
Patients were fasting 6 hours prior to PET/CT scan. PET/CT images were acquired 
using a Biograph 40 True Point scanner (Siemens, Erlangen, Germany), covering an 
area from the meatus of the ear to the proximal thigh. 18F-FDG was injected 
intravenously 60-120 minutes before starting the CT scan. Low-dose CT (120 kV, 50 
reference mAs) was performed for attenuation correction, and static PET images were 
collected at intervals of 3 minutes per bed position. Maximum standard uptake value 
(SUVmax) was measured in the tumor, and a volume of interest (VOI) was generated 
including voxels with SUV > 2.5. The VOI was used to estimate mean standard 
uptake value (SUVmean) and MTV. TLG was calculated as following; TLG = SUVmean 
x MTV (133, 152). 
 
3.3 Cell studies 
In this PhD-project we have used endometrial carcinoma cell lines and primary tumor 
cells to explore the expression of potential biomarkers and to establish orthotopic 
mouse models (paper I and II). 
 
3.3.1 Maintainance of cell cultures 
Endometrial carcinoma cell lines were grown at 37°C in a humidified atmosphere, 
with 5% CO2. Table 6 contains an overview of growth mediums and supplements 







Table 6: Medium and supplements for cell cultures 






10 100 IU/ml penicillin 
100 µg/ml streptomycin 








10 100 IU/ml penicillin 
100 µg/ml streptomycin 







I, II EMEM 
Lonza, Switzerland 
5 100 IU/ml penicillin 
100 µg/ml streptomycin 
2 mM ʟ-glutamine 






II DMEM  
Ham’s F-12  
(1:1) 
10 100 IU/ml penicillin 
100 µg/ml streptomycin 
2 mM ʟ-glutamine 
2.0 g/L sodium bicarbonate 






I, II EMEM 
Lonza, Switzerland 
10 100 IU/ml penicillin 
100 µg/ml streptomycin 
 
American type culture collection (ATCC), Dulbecco’s modified Eagle medium 
(DMEM), Eagle’s minimum essential medium (EMEM), Fetal bovine serum (FBS), 
International units (IU),  
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3.3.2 Cell transfection 
Transfection refers to the introduction of exogenous DNA into a cell. Transfection 
can be transient, or it can be stable by incorporating the new DNA into the recipient’s 
genome.  It is common for the transferred DNA-sequence to contain a selection 
marker, such as an antibiotic resistance gene, or a reporter gene (i.e. green fluorescent 
protein) to be able to distinguish successfully transfected cells from wild type cells. In 
our studies we have used Ishikawa (paper I and II) and Hec1B cells (paper II) that 
have been stably transfected with a luciferase expressing (luc+) vector (153, 154). 
Transfected cells (Hec1Bluc+ and Ishikawaluc+) were selected using 1 µg/ml puromycin 
(Sigma-Aldrich, St. Louis, MO, USA). Luciferase activity was confirmed by in vitro 
BLI using an Optix MX3 Time-Domain Optical Imager (ART Inc. Saint-Laurent, 
QC, Canada) 10 minutes after addition of 2.5 mg/ml ᴅ-luciferin (Promega, Madison, 
WI, USA).  
 
3.3.3 Flow cytometry 
Flow cytometry is a technology that allows simultaneous measurement of multiple 
physical characteristics of cells, such as size, granularity, or expression of proteins. In 
paper II the expression of four potential NIRF-imaging targets was explored in four 
endometrial carcinoma cell lines (AN3CA, Hec1B, Ishikawa and RL95-2) by flow 
cytometry. These four proteins (Activated leukocyte cell adhesion molecule 
(ALCAM), EpCAM, Insulin-like growth factor 1 receptor alpha (IGF1Rα), and 
L1CAM, Table 7) were all reported to be overexpressed or associated with poor 
prognosis in patients diagnosed with endometrial cancer (82, 84, 155-160).  Cells 
were washed twice with 1% bovine serum albumin (BSA)/phosphate buffered saline 
(PBS) before incubation with antibody for 30 minutes on ice protected from light. 
Cells were washed again, and resuspended in PBS. Samples were analyzed using an 
AccuriTM C6 (BD Biosciences, San Jose, CA, USA) flow cytometry system, and 
results were processed using CFlow Sampler Analysis 1.0 software. 
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Table 7. Specifications of antibodies used for flow cytometry in paper II. 
Target Clone Conjugate 
ALCAM 3A6 













Sino Biological Inc., China 
PE 
Activated leukocyte cell adhesion molecule (ALCAM), Epithelial cell adhesion 
molecule (EpCAM), Insulin-like growth factor 1 receptor alpha (IGF1Rα), L1 cell 
adhesion molecule (L1CAM), phycoerythrin (PE). 
 
3.3.4 Antibody conjugation 
For in vivo fluorescence imaging in paper II an anti-human EpCAM antibody 
(MCA1870EL, clone VU-1D9; BioRad, Hercules, CA, USA) was conjugated to 
AF680 using the SAIVI Rapid Antibodies Labeling Kit (Invitrogen, Waltham, MA, 
USA) as described by the supplier. Protein concentrations and degree of labeling was 
determined using a Nanodrop 1000 spectrophotometer (Thermo Scientific, Waltham, 
MA, USA).  
 
3.3.5 Proliferation and viability assays  
In paper II, proliferation and viability of wild type cells and cells exposed to an anti-
EpCAM antibody (MCA1870EL) was compared. Cell proliferation was assessed 
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using the CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, 
Madison, USA) as described by the supplier. All experiments were performed in 
triplicates. Proliferation was assessed by measuring absorbance at 490 nm one hour 
after addition of 20 µl of substrate. Absorbance was recorded using a TECAN 
Magellan Sunrise plate reader and TECAN Magellan software version 6.3 (both 
Tecan; Männedorf, Switzerland).  Apoptosis was evaluated by flow cytometry 
following 15 minutes of Annexin V/propium iodine staining (Thermo Fisher 
Scientific, Waltham, MA, USA).  
 
3.4 Animal studies 
All animal studies have been approved by the Norwegian State Commission for 
Laboratory Animals (FOTS ID 4036 - Paper I and FOTS ID 6735 - Paper II) and 
have been conducted according to the European Convention for the Protection of 
Vertebrates Used for Scientific Purposes.  Female non-obese diabetic severe 
combined immune deficiency gamma (NOD/SCID IL2r null (NSG)) mice were used 
for all animal studies. Mice were kept under pathogen-free conditions in individually 
ventilated cages, with a maximum of 5 animals per cage. Environmental conditions 
were highly controlled, with constant temperature of 21°C, 50% relative humidity, 
and 12 hours day/night schedule. Animals had ad libitum access to food and water. In 
Paper II animals were fed a chlorophyll-free diet (2018S Teklad Global 18% Protein 
Rodent Diet, Envigo, Cambridgeshire, UK or D10001, Research Diets Inc., New 
Brunswick, NJ, USA) to reduce background signal in fluorescent images. When 
developing clinical signs of disease, manifested by 10-15% weight loss, abdominal 
distention, lethargy or ruffled fur, animals were anesthetized and sacrificed by 
cervical dislocation. Tissue samples were collected during necropsy, and fixed in 
formalin or snap-frozen in liquid nitrogen. Full sections were prepared from FFPE-
tissue and stained with hematoxylin and eosin for histological examination.  
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3.4.1 Generation of orthotopic xenograft models 
Mice were anesthetized by i.p. injection of tribromoethanol (250 mg/kg) dissolved in 
2 methyl-2 butanol and diluted in sterile water to a final concentration of 12.5 mg/ml. 
Prior to surgery 0.1 mg/kg buprenorphine was injected s.c. for analgesia. Abdominal 
fur was removed and the skin disinfected before placing the animal in dorsal 
recumbency on a heating pad. A 1 cm long incision was made in the caudal abdomen, 
and the left uterine horn exteriorized. The uterine lumen was sealed by a temporary 
ligature to prevent vaginal leakage prior to injection of tumor cells (typically 106 cells 
per mice) suspended in BD Matrigel Basement Membrane Matrix (BD Biosciences, 
San Jose, USA) as demonstrated in Figure 4. After the cell suspension polymerized, 
the ligature was removed and the uterine horn replaced. Skin and musculature were 
closed separately using absorbable sutures. Animals were rehydrated by s.c. injection 
of saline before being placed under a heating lamp and observed until full recovery. 









Figure 4. Generation of orthotopic endometrial carcinoma xenograft. The left 
uterine horn was exteriorized and sealed off by a temporary ligature. A needle was 
inserted through the uterine wall, and cell suspension injected into the uterine lumen.  
 
In Paper I the human origin of uterine xenograft tumors was confirmed by IHC. 4 
µm thick full sections were made from FFPE-tissue and stained for human ERα (SP-
1). Species specificity of the antibody was validated by comparison with sections 
stained with a non-species specific ERα antibody (HC-20). IHC staining was 
performed as described in section 3.1.3 and Table 4. 
 
3.4.2 Patient derived xenografts 
Fresh tumor tissue was collected during hysterectomy of endometrial carcinoma 
patients treated at HUS, and kept on ice until further processing. Tissue samples were 
manually dissociated and filtered through a 40 µm pore filter (Fisher Scientific, 
Hampton, NH, USA). Cells were centrifuged at 900 rpm for 4 minutes, before 
resuspension in BD Matrigel Basement Membrane Matrix. Orthotopic implantation 
of cells was performed as described in the previous section. Mice (P0 generation) 
were euthanized when developing clinical signs of disease, and cell suspension 
prepared from the uterine tumor before re-implantation in a new generation of mice 
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(P1). This process was continued in each generation to maintain the PDX models. 
Information regarding the individual PDX models is found in Table 8. 
 





Histologic subtype/grade  
(donor tumor) 
Paper Generation (P) 
1 69 Grade 3 endometrioid 
endometrial carcinoma 
I, II P0-P2 
2 75 Serous endometrial 
carcinoma 
II P1 
3 65 Grade 1 endometrioid 
endometrial carcinoma 
II P1 





3.4.3 In vivo treatment study 
In paper II 24 mice were orthotopically implanted with short-term cultured primary 
tumor cells (PDX 4, Table 8). After four weeks (day 28), treatment with paclitaxel 
(12 mg/kg i.p. twice weekly, n = 8 mice), trastuzumab (10 mg/kg i.p. once weekly, n 
= 8 mice) or vehicle (n = 8 mice) was initiated. In vivo tumor growth was monitored 
using EpCAM-AF680 NIRF imaging pre- (day 26) and post treatment (day 55). 18F-
FDG PET/CT imaging was performed on day 47. Animals were euthanized on day 57 
or prior to this if developing clinical signs of disease. After euthanasia, uterine tumors 
were weighed and tissue samples collected and fixed in formalin. 
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3.5 Small animal imaging 
Several small animal imaging modalities exist, and we have used BLI, NIRF, MRI 
and PET-CT to detect and monitor tumor growth in our endometrial carcinoma 
xenograft models. Figure 5 demonstrates the different imaging techniques used in this 
PhD-project. 
 
3.5.1 Optical imaging 
Bioluminescence  
BLI was performed to monitor tumor growth in mice orthotopically implanted with 
endometrial carcinoma cell lines (Ishikawaluc+ – Paper I and II or Hec1Bluc+ – Paper 
II). Images were obtained using an In-Vivo FX PRO molecular imaging system 
(Carestream Health Inc., Rochester, NY, USA, Paper I) or an Optix MX3 Small 
Animal Molecular Imager (ART Inc., Saint-Laurent, QC, Canada, Paper II). 
Independent of the type of scanner, mice were injected i.p. with ᴅ-luciferin (150 
mg/kg) 10 minutes prior to imaging. Animals were anesthetized with 3% isoflurane 
(IsoFlo vet.; Zoetis, Helsinki, Finland) for induction and 1-2 % for maintenance. BLI 
was performed weekly, and images were analyzed using Carestream MI software 
(Standard Edition, v.5.0.6.20, Carestream Health Inc., Paper I) or Optix OptiView 
software (Paper II), and total bioluminescent signal was measured after manually 
defining a region of interest (ROI) of the abdomen and thorax. Mice that failed to 
develop bioluminescent signal were excluded from the studies. Ex vivo imaging of 
organs was performed to confirm the origin of the bioluminescent signal. 
 
 
Near Infrared Fluorecent Imaging 
NIRF imaging was applied to monitor disease progression and therapeutic response 
in endometrial carcinoma mouse models in Paper II. Mice were injected 
intravenously with 50 – 75 µg EpCAM-AF680 24 hours before imaging. Fur was 
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removed immediately prior to imaging, and the bladder was manually emptied. NIRF 
imaging was performed using the Optix MX3 Time-Domain Optical Imager (ART 
Inc., Saint-Laurent, QC, Canada), ex = 670 nm, em = 700 LP, raster scan points 1.5 
mm apart. In the cell line based model ROIs containing the abdomen and thorax were 
used for measuring of fluorescent signal in in vivo images, and ROIs surrounding 
each organ in ex vivo images. For measurement of fluorescent signal in PDX models 
the image with the largest tumor area was identified for each mouse.  A ROI was 
drawn around the tumor, and subsequently applied to all individual images from the 
same mice. Imaging data was analysed using the Optix OptiView software (version 
2.02; ART Inc., Saint-Laurent, QC, Canada). A tumor-free mouse injected with a 
corresponding dose of EpCAM-AF680 was imaged as control. 
 
3.5.2 Magnetic resonance imaging 
In Paper I MRI was used to visualize uterine tumor in the cell line based orthotopic 
endometrial carcinoma mouse model (Ishikawaluc+). Images were obtained by a 7T 
horizontal-bore preclinical scanner (Pharmascan 70/16, Bruker Corporation, 
Germany), using a 40 mm mouse body quadrature volume resonator in a single-coil 
configuration. 3% sevoflurane was used for anesthesia during imaging. A T2-
weighted rapid acquisition with relaxation enhancement (RARE) sequence (Echo 
time/repetition time (TE/TR) = 36/4300 ms, 2 averages, matrix 256 x 256, field of 
view (FOV) 3.2 x 3.2, 1 mm slice thickness) was used for tumor identification and 
estimation of tumor size. T1-weighted RARE sequences (TE/TR = 9/1000 ms, 4 
averages, matrix 256 x 256, FOV 3.2 x 3.2 cm, 1 mm slice thickness) were employed 
to obtain images before and after i.v. injection of a gadolinium based contrast agent 
(Dotarem, Guerbet, USA)(0.1 mmol/kg). DWI (TE/TR = 24.6/3100 ms, 2 averages, 
matrix 128 x 128, FOV 3.2 x 3.2 cm, 1 mm slice thickness, and 3 diffusion directions 




3.5.3 PET/CT imaging 
Both cell line based- and PDX-models were monitored by PET/CT during disease 
progression and/or when developing signs of clinical disease. 18F-FLT (Paper I) or 
18F-FDG (Paper I and II) were used as tracers. Integrated PET/CT whole-body 
images were collected using a nanoScan PC PET/CT (Mediso Medical Imaging 
Systems Ltd, Budapest, Hungary), with spatial resolution 800 µm (PET) and 30 µm 
(CT). PET detectors consisted of LYSO crystals, and acquisition was performed in 
1:5 coincidence and normal count mode. With exception of the PDX treatment study 
in paper II where mice were fasted overnight before PET/CT imaging, scans were 
obtained without prior fasting. Two mice were imaged simultaneously using a dual 
mouse bed with integrated system for heating and anesthesia. Animals were 
anesthetized with 3% sevoflurane (SevoFlo vet.; Zoetis, Parsippany, NJ, USA) during 
imaging. 18F-FDG was injected i.v. when starting the PET-scan. Total acquisition 
time was 1 hour, and a static image was reconstructed from the last 30 minutes. 18F-
FLT was injected i.v. 30 minutes prior to scanning, and the duration of the scan was 
30 minutes. In both cases, helical whole-body CT scans (50 kVP tube energy, 300ms 
exposure time, 720 projections, binning 1:4) were acquired for anatomical orientation 
and attenuation correction of PET images. Reconstruction of PET images were 
performed using the Tera-Tomo 3D ordered subset expectation maximization 
algorithm, correcting for depth-of-interaction, radionuclide decay, randoms, crystal 
dead time, detector normalization and attenuation. Detector coincidence mode was 
1:3, 4 interations and 6 subsets, no filtering. CT images were reconstructed using 
RamLak filter. Automatic co-registration of PET- and CT images was performed, and 
voxel size for reconstructed images was 0.25x0.25x0.25 mm3 for CT and 0.4x0.4x0.4 
mm3 for PET. InterView Fusion software v. 2.02.055.2010 (Mediso Ldt., Budapest, 
Hungary) was used for further analyses of imaging data. SUV was calculated as: 
SUV = CPET(T)/(ID/BW), where CPET(T) equals the measured activity in tissue, ID 
the injected dose (kBq), and BW the body weight of the animal (kg) . A VOI with 
radius 1.5 mm was defined in the nuchal musculature, and SUVmean of this VOI used 
as reference tissue to identify presumed tumor tissue with SUV ratios of > 2 (18F-
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FLT, Paper I) and > 6 (18F-FDG, Paper I). In Paper II voxels with SUV values > 
2.5 were included in measurements of SUVmean and MTV. Semi-automatically VOIs 
were drawn for both primary uterine tumors and presumed metastases, and MTV and 
SUVmean calculated. TLG (
18F-FDG scans) was estimated as TLG = FDG-SUVmean x 
MTV, and a similar parameter (FLT-SUVmean x MTV) based on the same equation 
was calculated for 18F-FLT –scans as a measure of total number of metabolically 
active tumor cells. 
 
 
Figure 5. In vivo small animal imaging. Optical imaging enables monitoring of 
tumor growth over time, here demonstrated by bioluminescent imaging of the same 
mouse over five consecutive weeks (A). PET/CT visualizes uterine tumors, in this 
case using 18F-FDG as tracer (B). Uterine tumor is also detectable by MRI, on both 
T2-weighted (C) and T1-weighted images before (D) and after (E) injection of 
contrast. Thin arrows point out the uterine tumor, while the thick arrow is directed at 
intrauterine fluid that has accumulated cranial to the tumor. Bladder (b), heart (h), 




Categorical variables were analysed using the Pearson χ2 test or Fisher’s exact test, 
while continuous variables were evaluated using the Mann-Whitney U test. The 
Kaplan-Meier method was used to generate disease-specific survival curves, and 
survival between groups was compared using the log-rank test (Mantel-Cox).  Date of 
primary surgery was used as entry date, and time of death due to endometrial 
carcinoma defined as endpoint. Patients who were alive on the last day of follow-up 
or died from other causes were censored. In in vivo mouse models, time of 
implantation was used as entry date, and time of sacrifice as endpoint. The prognostic 
impact of ASRGL1 on survival (corrected for other variables with known prognostic 
impact) was evaluated by the Cox proportional hazard regression model, and the 
ability of ASRGL1 to predict lymph node metastasis evaluated by binary logistic 
regression. Kappa value ( ) or intraclass correlation coefficient (ICC) was calculated 
to assess interrater reliability of immunohistochemical scoring in biomarker studies. 
ICC estimates were calculated by a single rater absolute agreement, two-way random 
effects model. Pearson correlation was used to evaluate the relationship between 
bioluminescent and fluorescent signal in vivo. One-way analysis of variance with 
Tukey post hoc testing was applied to compare tumor weights, NIRF-signal and 
MTV values between groups of mice treated with paclitaxel, trastuzumab or saline. 
Statistical analyses were performed using the software package SPSS (IBM, Armonk, 
NY, USA) version 24, and P-values < 0.05 were regarded statistically significant. 
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4. Summary of results 
Paper I: We successfully established orthotopic mouse models from both an 
endometrial carcinoma cell line (Ishikawaluc+) and cells from endometrial carcinoma 
biopsies. In the cell line model increasing bioluminescent signal was observed over 
time, along with gradual development from focal towards a more diffuse abdominal 
signal - indicating tumor growth and metastatic spread. MRI was performed in a 
mouse from the Ishikawaluc+ model, and uterine tumor was detected in both T1- and 
T2-weighted images. Tumor was observed to moderately enhance in T1-series after 
i.v. injection of contrast, and ADC-mapping revealed restricted diffusion within 
tumor tissue. PET/CT imaging of mice in the cell-line based model revealed 18F-
FDG/18F-FLT-avid tumor tissue in the uterus of 6 out of 7 mice. Increasing MTV and 
SUVmean x MTV was observed in both primary tumors and metastases. Although the 
calculated MTV and SUVmean x MTV values of the different tracers were not directly 
comparable, both 18F-FDG and 18F-FLT seemed equally able to identify tumor tissue 
and monitor disease progression. PET/CT and MRI findings in the Ishikawaluc+ 
mouse model were comparable to imaging characteristics of human endometrial 
carcinoma patients. 18F-FDG and 18F-FLT PET/CT also detected uterine tumors in 
mice orthotopically implanted with patient-derived tumor cells.  
 
Paper II: When exploring the presence of selected surface proteins (ALCAM, 
EpCAM, IGF1Rα and L1CAM) in endometrial carcinoma cell lines (AN3CA, 
Hec1B, Ishikawa and RL95-2) EpCAM was found to have the highest overall 
expression, and was particularly abundant in the Ishikawa cell line. Positive EpCAM 
protein expression was found in 98% of hysterectomy samples in a cohort of 153 
endometrial carcinoma patients, and the majority of these demonstrated strong 
positive staining (SI: 6-9). An anti-human anti-EpCAM antibody was conjugated to 
an AF680 fluorophore, and used to detect EpCAM expression both in vitro and in 
vivo. Both BLI and EpCAM-AF680 NIRF imaging enabled visualization of uterine 
tumors in orthotopic cell line-based models, however; EpCAM-AF680 NIRF imaging 
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enabled earlier and more precise visualization of metastatic lesions compared to BLI.  
Signal origin was confirmed by ex vivo imaging of organs, using both BLI and 
EpCAM-AF680 NIRF imaging. EpCAM-AF680 NIRF imaging successfully detected 
uterine tumors in multiple endometrial carcinoma PDX models, including models 
with relatively low expression of EpCAM. We found EpCAM-680 NIRF to be 
superior to 18F-FDG PET/CT in monitoring of PDX tumors, providing better contrast 
and earlier detection of tumor in most cases. Mice orthotopically implanted with cells 
from a patient diagnosed with endometrioid grade 3 endometrial carcinoma were 
treated with vehicle control (n = 8), paclitaxel (n = 8) and trastuzumab (n =8).  
Animals were monitored in vivo using EpCAM-AF680 NIRF and 18F-FDG PET/CT 
imaging, without observing any effect of treatment based on mean NIRF-signal 
(F(2,21) = 1.07, p = 0.36) or MTV (F(2,14) = 0.76, p = 0.49). This was consistent 
with post mortem examinations where no significant differences in tumor weights 
were found between the three groups (F(2,21) = 0.07, p = 0.93). Presence of tumor 
cells in the uteri of mice was confirmed by histological examination.  
 
Paper III: We explored the expression of ASRGL1 in tissue samples from a large, 
prospectively collected patient cohort, and found that 1% of CAHs, 21% of primary 
endometrial tumors, and 77% of metastatic lesions have low levels of ASRGL1. 
Antibody validation was performed by staining 607 primary tumors for ASRGL1 
using two different antibodies, demonstrating significantly correlating staining 
indexes (P < 0.001) and similar prognostic value. Low expression of ASRGL1 was 
associated with characteristics of aggressive endometrial carcinoma, including high 
age, FIGO stage III-IV, high grade and non-endometrioid histology (P < 0.001 in all). 
A significant overlap between ASRGL1 mRNA and ASRGL1 protein was observed 
(P < 0.001), and low expression of both ASRGL1 mRNA and protein expression was 
associated with poor disease specific survival (P < 0.001). In multivariate analyses 
ASRGL1 had independent prognostic value, both in the total patient population 
(Hazard ratio (HR): 1.53, 95% confidence interval (CI): 1.04 – 2.26, P = 0.031) and 
in patients with endometrioid endometrial carcinoma (HR: 2.64, CI: 1.47 – 4.74, P = 
0.001). The highest proportion of metastatic lesions with low ASRGL1 expression 
 70 
(90%) was found in patients with non-endometrioid endometrial carcinoma, 
compared to endometrioid endometrial carcinoma patients where only 63% of 
metastases had low levels of ASRGL1.  In cases with low ASRGL1 expression in 
primary tumor, ASRGL1 was most often lost in corresponding metastases. In most 
patients with multiple metastases, similar expression of ASRGL1 was found in all 
metastatic lesions from the same individual. ASRGL1 was also more frequently lost 
in metastases than the hormone receptor ERα. 
 
Paper IV: 20% (n = 227) of patients expressed low levels of ASRGL1 in 
preoperative samples. For 484 patients ASRGL1 status in hysterectomy specimen 
was known, and similar expression of ASRGL1 in curettage and corresponding 
hysterectomy sample was observed in 85% (n = 413) of cases (P < 0.001). Low 
expression of ASRGL1 was significantly associated with pre-operatively available 
parameters related to aggressive disease, such as high risk curettage histology (P < 
0.001), combined ERα/PR loss (P < 0.001) and large tumor volume on MRI (P = 
0.026). Significant associations between low ASRGL1 level and post-operatively 
assessed features related to aggressive endometrial carcinoma were also observed, 
including high FIGO stage, non-endometrioid histology, and high grade (P < 0.001 
for all). ASRGL1 was found to have independent prognostic value in a multivariate 
survival analysis adjusting for age, FIGO stage, histological type and grade (HR: 
1.63, CI: 1.11 – 2.37, P = 0.012). Within the subgroup of patients with low risk 
curettage histology low ASRGL1 expression had an independent impact on survival 
when adjusted for age and FIGO stage (HR: 2.54, CI: 1.44 – 4.47, P = 0.001). 
Patients with low expression of ASRGL1 had a higher frequency of metastatic lymph 
nodes compared to patients with high ASRGL1 expression (23% versus 10%, 
respectively, P < 0.001), and low ASRGL1 level independently predicted lymph node 





5.1 Preclinical models of endometrial carcinoma 
5.1.1 In vitro models 
 
Preclinical models based on commercially available cell lines have been a 
cornerstone in cancer research for decades, and have contributed to achieving 
valuable insights in cancer biology (115, 162, 163). A variety of laboratory methods 
are available to study different properties of cells in vitro, and cell line studies are 
useful in generation and initial testing of hypotheses. Cell line models are low cost 
compared to animal models, and results can be retrieved quickly. Although there are 
many applications where cell line studies can be useful, these models generally fail to 
reproduce the complex physiological environment of human tumors. Cell lines are 
typically cultured as monolayers on plastic surfaces, thus preventing the formation of 
three-dimensional structures. Growth mediums often contain a variety of 
supplements, and may not be representative of the physiological microenvironment in 
vivo. Overall, these artificial conditions may affect the genetic, morphologic and 
physiologic properties of the cells (162, 163). Another weakness of cell cultures is 
that they lack a normal microenvironment and are devoid of stromal cells, immune 
cells and blood vessels. Additionally, cell lines derived from normal endometrial 
tissue are seldom available as controls. Combined, these factors contribute to 
reducing the clinical relevance of cell culture models (115). 
 
One approach to improve the clinical validity of in vitro models is to establish short-
term cultures of primary tumor cells derived from patient biopsies. Primary cell 
cultures are suggested to retain genetic and molecular traits of the primary tumor, and 
thus be more representative cancer models compared to conventional cell lines. 
However, culturing of primary patient cells is challenging as these often fail to thrive 
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in vitro. Certain tumors may be more difficult to culture than others, and thus the 
distribution of subtypes available as in vitro models may not be representative of the 
prevalence of subtypes in the human population. Intratumoral heterogeneity poses 
another challenge, as the part of the tumor used for generation of primary cell culture 
may not reflect the characteristics of the entire tumor. Additionally, selection of 
clones that are more prone to adhere and grow under non-physiological conditions 
may lead to reduced cellular heterogeneity in the culture compared to the original 
sample (113). In paper IV we established short-time cultures of primary tumor cells 
to achieve sufficient cell numbers for simultaneous implantation of multiple mice. 
This represents a potential limitation of our study as in vitro propagation of cells, 
although only for a few passages, may result in phenotypic alterations. However, for 
endometrial carcinoma it has been reported that patient derived short-time cultures 
and xenografts maintain the same genomic traits as the corresponding human primary 
tumor (113). Short-time culturing of cells prior to xenografting may thus be 
justifiable, however; more research is needed to elucidate the strengths and 
weaknesses of models that have been generated using this approach. 
 
Recently, generation of organoid cultures has been presented as a novel approach to 
improve in vitro models of human cancer. Organoids are self-organizing 3D cultures 
containing both stem cells and differentiated cells that mimic the tissue of origin, and 
can be generated from patient biopsies. Human organoid cultures have been 
established from both endometrial carcinoma tissue and normal adjacent 
endometrium, and demonstrated to reproduce the molecular and histological 
phenotype of the donor tissue (164-166). Organoid cultures can be used as high-
throughput systems for developing and studying new therapies, and findings may be 
validated in a systemic setting in vivo by using organoid-derived mouse models. 
Altogether, organoids and organoid-based animal models may serve as valuable 
platforms for preclinical research (166, 167).   
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5.1.2 Orthotopic mouse models 
One of the major challenges in cancer research is that the results from preclinical 
animal studies are difficult to reproduce in human patients (86, 96), and it is reported 
that less than 8% of new drugs that were efficient in animal models make it through 
clinical trials (168). The low translational success rate is often attributed to cancer 
models that poorly simulate the human disease setting, and possible reasons include 
differences in physiology between species and failure to recapitulate the complexity 
of the cancer (168).  Development of clinically relevant mouse models is thus of the 
highest importance in order to improve the congruence between preclinical 
experiments and clinical studies. 
 
Methodological considerations – establishment of in vivo models 
In paper I and II we successfully established orthotopic mouse models from both 
endometrial carcinoma cell lines and patient primary tumors. Generation of uterine 
xenografts was performed by transmyometrial injection of cancer cells. Transvaginal 
injection of tumor cells is also possible; however, the transmyometrial approach is 
reported to have higher engraftment rates (97). Several previously reported orthotopic 
endometrial carcinoma models have been generated by implanting tumor tissue on the 
posterior surface of the uterus (105, 106, 109). Although this intraabdominal 
approach may provide a more appropriate microenvironment compared to 
subcutaneous tumors, it may not fully recapitulate the conditions of the endometrium 
in uteri. The implantation of cancer cells directly into the uterine lumen may 
contribute to a more clinically relevant disease progression, as tumor is established in 
the endometrium before progression towards myometrial infiltration, peritoneal 
dissemination, and lymphatic and hematogenous spread (97).  
In paper I and II we used NSG mice for orthotopical implantation of human tumor 
cells in order to facilitate engraftment. In addition to the severe combined 
immunodeficiency-mutation, NSG mice inhabits an interleukin 2 receptor gamma 
chain deficiency, lack functional T-cells, B-cells and natural killer cells and have 
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deficient cytokine signaling (114). NSG mice are reported to have high take rates 
(towards 95-100%), and are thus highly suitable as xenograft models (169).  
However, the lack of a functional immune system unavoidably offers a tumor 
environment that differs from the human setting, and may affect cancer growth. The 
possibility to study interactions between tumor and the microenvironment is also 
limited (86, 93, 98, 102). A potential solution to these problems is development of 
personalized immune animal models, where bone marrow aspirates from a human 
patient can be injected into the mouse prior to tumor xenografting (86, 98, 170). Still, 
even though immunocompetent models would be highly valuable in preclinical 
research, establishment of such models is technically demanding and requires 
collection of several invasive biopsies from patients (170). 
 
Patient derived xenograft model 
Several PDX-models were successfully established during this PhD-project, 
representing tumors of low- and high grade endometrioid as well as non-
endometrioid histologies. The ability to generate mouse models from different types 
of primary endometrial tumors is highly beneficial, as using multiple xenograft 
models in testing of hypotheses and evaluation of drug response (similarly to clinical 
trials) may improve the translational relevance of future preclinical studies (171).   
 
One major threat to the clinical validity of PDX models is intratumor heterogeneity. 
Xenografts are established from limited amounts of tissue in tumor biopsies, and the 
heterogeneity of the primary tumor may thus not be fully comprehended in the PDX 
model. Still, comparative studies of human endometrial tumors and their 
corresponding xenografts found high degree of genomic and phenotypic preservation 
(113). Both implantation of tissue pieces (97, 111, 113, 172, 173) and cell suspension 
(paper I and II) have been demonstrated to enable endometrial carcinoma 
engraftment. Most reported endometrial carcinoma models have been established 
from tissue pieces. This approach is beneficial, as the tissue architecture of the 
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primary tumor is retained. The weakness of this method is that only small pieces of 
tumor can be implanted, potentially making the xenograft representative only to 
minor parts of the primary tumor. Although losing the three-dimensional structure, 
the advantage of using single cell suspension is that tumor can be dissociated to 
generate a heterogeneous sample that may represent a larger proportion of the 
patient’s tumor (171). However, processing of tumor biopsies may reduce the amount 
of viable tumor cells and reduce engraftment rates. Another challenge for PDX 
models is that human stroma is demonstrated to be replaced by murine stromal cells 
after xenografting. This could potentially limit the clinical value of these models - 
especially in studies of tumor/microenvironment interactions and therapies directed 
towards the stromal compartment (86, 111).  In order to address this issue co-
implantation of patient-matched stromal cells such as mesenchymal stem cells or 
cancer associated fibroblasts has been suggested (170). 
 
Although most reported PDX models of endometrial carcinoma have been generated 
by subcutaneous implantation of tumor cells or tissue, orthotopic models have also 
been described (97, 113). In paper I and II we established orthotopic xenografts 
from several endometrial carcinoma patients. When comparing our cell line based 
and patient-derived mouse models, a number of features suggest that the PDX-models 
are superior in resembling clinical endometrial carcinoma. Firstly, several of the mice 
in our PDX models have displayed vaginal bleeding towards the later stage of disease 
development. So far we have not observed the same in any of our cell line based 
models. This similarity in clinical manifestation is interesting, as vaginal bleeding is 
the most common presenting symptom of endometrial carcinoma in human patients 
(10). Secondly, while our cell line models usually develop high degree of 
intraperitoneal tumor dissemination and distant metastases, PDX tumors are more 
often confined within the uterus. The latter is more comparable to human endometrial 
carcinoma, where the majority of patients are diagnosed with low stage disease (174).  
One important goal in preclinical research is to establish relevant models for studies 
of therapeutic effect. Treatment studies conducted in PDX models are reported to 
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have highly similar drug response compared to human clinical trials (171). This is 
especially observed in one-to-one studies where the treatment responses of PDX 
models are compared to the response in the corresponding human donor tumor (86). 
Several in vivo drug treatment studies have been conducted in subcutaneous 
endometrial carcinoma PDX models. Sensitivity to the dual pan-PI3K/mTOR 
inhibitor NVP-BEZ235 and the MEK-inhibitor AZD6244 was observed in mice with 
confirmed KRAS, PTEN and PIK3CA mutations in tumor (111), while another study 
demonstrated that the antibody-drug conjugate IMGN853 had antitumor effects in a 
PDX model of serous endometrial carcinoma (173). However, subcutaneous tumors 
may display diverging response to therapy compared to primary uterine tumors due to 
differences in growth pattern and environmental factors, and orthotopic models may 
thus be more favorable for evaluation of treatment. In paper II we demonstrated an 
orthotopic PDX model that can be used for therapeutic studies. To evaluate the 
feasibility of the model, mice were treated with paclitaxel or trastuzumab. Paclitaxel 
is a cytostatic drug that stimulates microtubule polymerization and mitotic arrest 
(175) and was chosen as it is commonly applied as first-line adjuvant chemotherapy 
in treatment of endometrial carcinoma patients (14). Trastuzumab is a HER2-
targeting antibody which has been suggested as a candidate drug to treat endometrial 
carcinoma patients with HER2-positive tumors. The clinical value of this treatment 
has so far been hampered by poorly understood mechanisms of acquired resistance 
(64). However, combinational therapy where trastuzumab is added to the standard 
paclitaxel/carboplatin regimen has been suggested to improve outcome (176). In the 
current study, trastuzumab was selected based on positive HER2 immunostaining in 
the primary human tumor. Neither paclitaxel nor trastuzumab treatment demonstrated 
statistically significant inhibitory effects on tumor growth. Still, this PDX model may 
have potential value in studies of drug resistance mechanisms as well as in studies of 
other candidate drugs.  
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5.1.3 Small animal imaging  
The use of small animal imaging in cancer research has increased enormously over 
the last years, as development of non-invasive longitudinal imaging techniques has 
allowed for in vivo studies of tumor growth, metastatic spread, and evaluation of 
therapeutic response. Molecular imaging methods reflect specific tumor properties, 
including glucose metabolism (18FDG-PET), cell division (18FLT-PET) and EpCAM 
expression (EpCAM-AF680 NIRF). Evaluation of tumors using several modalities 
may thus provide valuable information on tumor biology beyond anatomical 
localization and evaluation of size (114, 116, 117). Molecular imaging is particularly 
interesting as changes in tumor metabolism may be detectable before changes in 
tumor size, which may be important for early therapeutic evaluation. 
 
Optical imaging is a commonly applied technique for preclinical imaging, and BLI is 
reported to be an efficient imaging method to detect tumor growth and metastatic 
dissemination in several cancer models (97, 113, 120, 154). In paper I and II BLI 
was applied to visualize tumor development in cell line based orthotopic endometrial 
carcinoma models. Although being highly specific and with a high signal-to-
background ratio, BLI is only applicable in models where luc+ genes have been 
introduced. This usually limits the area of use to animal models generated from 
conventional cell lines. Additionally, the process of introducing the reporter gene 
must be repeated each time new models are established. BLI has been used to follow 
tumor growth in an orthotopic PDX model generated from luciferase-transfected 
short-time cultured endometrial carcinoma cells (113). However, transfection of 
primary patient cells may potentially disturb the tumor genome and result in an 
altered cell phenotype. In order to avoid this risk we have explored reporter gene-
independent imaging alternatives to visualize tumor growth in our PDX models. In 
paper II we identified EpCAM as a candidate target protein for NIRF imaging in 
orthotopic endometrial carcinoma xenografts. EpCAM is an adhesion molecule 
located on the basolateral membrane of epithelial cells, and is reported to be highly 
expressed in several epithelial cancers (177). As EpCAM-AF680 NIRF imaging is an 
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antibody-based application, the method is easily applicable for in vivo imaging in 
multiple endometrial carcinoma models. We evaluated the performance of BLI and 
EpCAM-AF680 NIRF imaging in orthotopic cell line-based models (paper II). 
Although BLI and EpCAM-AF680 NIRF produced similar visualization of primary 
tumors in models derived from Ishikawaluc+ or Hec1Bluc+ cells, EpCAM-AF680 NIRF 
imaging enabled earlier and better delineation of distant metastases, suggesting that 
EpCAM-AF680 is highly feasible for evaluation of metastatic disease. However, it is 
worth noting that the imaging system we are using is optimized for fluorescent 
imaging, and different results may have been achieved if an imaging system more 
optimized for BLI had been applied. EpCAM-AF680 was also found to provide 
excellent visualization of uterine tumors in multiple PDX models representing 
different histologic types of endometrial carcinoma, and was found to be superior to 
18F-FDG PET/CT. Even uterine tumors in PDX models with low expression of 
EpCAM (PDX 4) were detected by EpCAM-AF680 NIRF imaging, thus highlighting 
the feasibility of this imaging modality for preclinical applications. 
 
Optical imaging is highly valuable in studies of orthotopic xenograft models. There 
are however some challenges, and we have addressed these to limit their impact 
where possible. In paper I and II we found BLI and EpCAM-AF680 NIRF imaging 
to be feasible for detection of both primary tumor and metastatic lesions. However, as 
these methods only provide two-dimensional images we were not able to accurately 
decide which organ the signal originated from in vivo. Also, distinguishing tumor 
lesions within the parenchyma from lesions in the peripheral margins of an organ was 
not possible. We thus performed ex vivo imaging and histologic evaluation of organs 
to confirm the anatomical origin of the signal. Limited penetration of signal 
combined with signal scattering and absorbance in tissue represents another 
challenge. As photons in the near-infrared spectrum have better tissue penetration 
compared to photons with wavelengths of below 500 or above 1100 nm (140), we 
chose to use AF680 to achieve high image quality. NIRF imaging of uterine tumors 
may be hampered by high background signal due to autofluorescence in the 
gastrointestinal tract and accumulation of fluorophore in urine. For the experiments in 
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paper II we attempted to minimize these problems by emptying the bladder prior to 
imaging and feeding the animals a chlorophyll-free diet.  
 
PET/CT and MRI have been demonstrated to detect tumors and visualize treatment 
response in several xenograft models, including breast cancer (178), colorectal cancer 
(179) and Ewing sarcoma (180). Although the basic principles behind these 
techniques are the same for humans and animals, specialized machines for small 
animal imaging have been developed due to body size and technical requirements for 
optimal resolution (116, 117).  In paper I we demonstrated that PET/CT using 18F-
FDG and 18F-FLT as tracers can be used to visualize orthotopic endometrial 
carcinoma xenografts. These tracers were chosen as they represent different 
metabolic processes characteristic of cancer cells (increased glucose metabolism and 
proliferation, respectively). Additionally, 18F-FDG is used for preoperative imaging 
of endometrial carcinoma patients in several hospitals, and findings in preclinical 
models may thus have potential translational value.  In paper II 18F-FDG PET/CT 
imaging was performed in PDX-models originating from multiple patients with 
different histologic backgrounds, and also applied to evaluate paclitaxel and 
trastuzumab treatment in an orthotopic endometrial carcinoma PDX model. One 
major benefit with PET/CT imaging is that the data from the functional PET scan is 
merged with the anatomical information from the CT scan. This enables three-
dimensional evaluation of tumor lesions and the localization of the tumor can be 
more precisely pinpointed to a specific organ. However, 18F-FDG has a high 
background uptake in organs such as brain and kidneys, as well as increased uptake 
in inflammatory tissue, which can make oncological assessments difficult (129). 
Signal from small uterine tumors can also be camouflaged by physiological 
accumulation of tracer in nearby organs such as urinary bladder and intestine. This 
may partially explain why 18F-FDG PET/CT imaging failed to identify several of the 
small tumors in our PDX-models. Fasting animals and emptying the bladder prior to 
scanning may reduce unspecific signal, and improve the delineation of tumor against 
normal tissue. This was done prior to imaging of mice in the paclitaxel/trastuzumab 
treatment study (paper II), resulting in markedly reduced background signal 
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compared to previous experiments. MRI is also often applied in preoperative 
examinations of patients with endometrial carcinoma. In vivo MRI imaging of a 
mouse orthotopically implanted with an endometrial carcinoma cell line demonstrated 
that the uterine tumors in the xenograft model had hyperintense appearance on T2-
weighted images and restricted diffusion on ADC-maps; highly resembling the 
findings from MRI imaging in endometrial carcinoma patients (paper I). Although 
being a promising modality for imaging of endometrial PDX models, the value of 
MRI in preclinical studies remains to be confirmed through future in vivo 
experiments.  
 
5.2 Asparaginase-like protein 1 
5.2.1 Methodological considerations – biomarker studies 
Correct identification of high-risk patients and stratification of patients to appropriate 
treatment regimens is vital to improve the outcome of endometrial carcinoma. 
Biomarkers are central in these processes, and new, robust markers are needed. 
Before clinical implementation, new biomarkers should be validated in independent 
patient cohorts and their clinical utility should be assessed. Validation studies should 
include enough patients to provide sufficient statistical power, and should be 
conducted in patient groups which are representative for the whole population where 
the biomarker is intended to be used. Our patient series (HUS and MoMaTEC 
cohorts) contain a large number of patients that have been included prospectively 
over a long period of time. The comprehensive database of clinical- and follow up 
information combined with a biobank containing numerous biological samples serves 
as an excellent research platform, both to identify potential new biomarkers and to 
validate findings from other biomarker studies.  
 
In paper III and IV ASRGL1 protein expression was evaluated by IHC staining of 
TMAs. This is a high-throughput method where a large number of samples can be 
evaluated simultaneously. There are several advantages with using TMAs in research 
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settings, including reduced use of tissue, shorter analysis time and lower reagent costs 
(181). The ability to stain all samples simultaneously reduces the risk of batch effects 
and limits variations in staining technique. Selection of tissue for TMA preparation is 
performed by identifying the most representative areas with highest tumor cell 
content in FFPE sections, and may not fully comprehend the characteristics of the 
entire tumor. However, to compensate for the limited amount of tissue collected in a 
TMA core, three cores are selected from each biopsy. This makes it more likely that 
the TMA is representative of a larger part of the tumor. The TMA method has been 
validated in several studies, demonstrating high concordance between TMAs and 
corresponding full tissue sections (182-184). Still, new biomarkers identified by 
TMAs, including ASRGL1, should be validated in full sections prior to clinical 
implementation.  
 
IHC is a valuable tool for detecting molecular and functional properties in tissues, 
and may aid in stratification of tumors with an otherwise similar histology. 
Challenges when studying biomarkers include that scoring systems and cut-offs 
seldom are standardized and that separate institutions may use different protocols. 
Thorough studies must thus be performed to identify and validate the optimal staining 
conditions before new biomarkers are introduced in a clinical setting.  We have used 
a semi-quantitative scoring method to evaluate ASRGL1 protein expression (paper 
III and IV), where both the intensity and area of tumor with positive staining is 
assessed. This SI system is a well-established method in our laboratory (148), and has 
been applied for several antibodies in various tumor types (185-187). ASRGL1 
protein expression in tumor cells was scored without considering subcellular 
localization, as separate evaluation of nuclear and cytoplasmic staining has been 
reported not to be of additional value (146). Although making it more difficult to 
compare results between studies, using different scoring methods and cut-offs for 
validation could potentially also be beneficial in biomarker studies. In paper III and 
IV we have used SI: 0-1 as cut-off for low ASRGL1 expression, while others have 
defined low ASRGL1 as < 75% cells with positive staining without regarding 
intensity (146, 147). Irrespective of the different cut-offs and scoring systems we 
 82 
were able to validate the prognostic impact of ASRGL1, supporting that ASRGL1 is 
a robust biomarker in endometrial carcinoma.  
 
Assessing the reliability of the scoring method is also important in biomarker studies 
as good reliability is important for clinical use to ensure uniform diagnosis of 
patients. Interrater reproducibility describes the variation between two or more 
observers rating the same objects, and can be evaluated in several ways (i.e. ICC). In 
paper III, an ICC of 0.95 was calculated for ASRGL1 score (CI: 0.93 – 0.96), 
indicating excellent interrater reliability (188).  
 
 
5.2.2 ASRGL1 as a preoperative prognostic biomarker 
Pre-operative evaluation of curettage histology is important for risk stratification and 
surgical planning in endometrial carcinoma. Still, the histological assessment of pre- 
and post-surgical samples is reported to be discordant in 10 – 32% of cases (16-19, 
22). Clinical implementation of molecular biomarkers may contribute to 
identification of patients with high risk disease before surgery (189, 190).  Several 
candidates including ERα, PR, p53, Ki-67, and L1CAM have so far been explored 
(78, 82, 190, 191). With a few exceptions, these markers are yet not clinically 
applied. However, an ongoing study (MoMaTEC2, NCT02543710) is evaluating the 
performance of preoperative hormone receptor status (ERα/PR) in selecting 
endometrial carcinoma patients for lymphadenectomy. As ASRGL1 was validated to 
be a strong post-operative prognostic marker (paper III) we wanted to explore if 
ASRGL1 also could serve as a potential biomarker in pre-operative samples. 
Previously, low ASRGL1 expression combined with PR loss in preoperative samples 
has been reported to be a strong predictor of FIGO stage III-IV disease in 
endometrioid endometrial carcinoma (147). This is in accordance with our study 
(paper IV) where low expression of ASRGL1 was significantly associated with 
characteristics of aggressive disease, including high FIGO stage. We also found that 
low expression of ASRGL1 in pre-operative specimens had independent prognostic 
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value, both in the whole patient population and in patients with presumed low risk 
curettage histology. Altogether, this indicates that ASRGL1 status in curettage may 
be a valuable marker to improve pre-operative risk stratification in endometrial 
carcinoma. However, as we are the first to report ASRGL1 as an independent 
biomarker in preoperative samples, these findings remain to be validated. 
 
5.2.3 Preoperative biomarkers vs sentinel lymph node dissection  
In paper IV we found that patients with low ASRGL1 expression in preoperative 
samples were more likely to have metastatic lymph nodes at time of surgery 
compared to patients with high ASRGL1 expression. This was observed both in the 
whole patient population and in patients with assumed preoperative low risk 
histology. Low ASRGL1 also independently predicted lymph node metastasis when 
adjusting for curettage histology risk, suggesting that evaluation of ASRGL1 in 
preoperative samples may add valuable clinical information.  However, the clinical 
utility of preoperative markers to guide the decision on whether or not to perform 
lymphadenectomy has been debated, and sentinel lymph node removal has been 
suggested as a better alternative. Although sentinel lymph node dissection is 
associated with less post-operative complications than full lymphadenectomy (33-
35), it would still lead to prolonged operating time and increased risk of 
complications compared to no lymph node sampling. As most patients do not have 
metastatic lymph nodes it could be debated that sentinel lymph node removal is an 
unnecessary procedure in many cases and that molecular markers could be used to 
identify patients that may benefit from sentinel lymph node exploration. By only 
performing sentinel lymph node mapping in selected patients, one could potentially 
reduce both time and costs associated with surgical treatment of endometrial 
carcinoma. At the present time, a large proportion of patients with presumed low risk 
endometrial carcinoma are treated at hospitals without the equipment that is needed 
for sentinel lymph node mapping. In such settings, preoperative biomarkers could be 
used to identify patients that may benefit from undergoing more advanced surgical 
staging and referral to secondary/tertiary hospitals.   
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5.2.4 ASRGL1 as a post-operative prognostic marker 
In paper III we found that low expression of ASRGL1 protein in hysterectomy 
specimens has independent prognostic value in endometrial carcinoma patients, thus 
validating the findings from a retrospective study where loss of ASRGL1 protein 
expression was reported to independently predict poor disease specific survival in 
endometrioid endometrial carcinoma (146). Another study evaluated a set of IHC 
markers (ASRGL1, ER, HER2, Ki-67, L1CAM, MLH1, PR, p53), and identified low 
ASRGL1 and abnormal p53 expression as the best combination within this panel to 
predict disease-free and disease-specific survival (147).  We are however the first to 
demonstrate that ASRGL1 has independent prognostic value in the whole patient 
population (paper III), not only in patients with endometrioid endometrial 
carcinoma. As there are currently no IHC biomarkers in clinical use to recommend 
adjuvant chemotherapy in endometrial carcinoma patients (192-194) and risk 
stratification is based on traditional parameters such as FIGO stage and histological 
grade (30), assessment of ASRGL1 status in hysterectomy samples could potentially 
provide clinically relevant information. Patients with grade 1-2 endometrioid 
endometrial carcinoma are considered to have low risk disease and will usually not 
receive adjuvant treatment. Some of these patients will however experience disease 
relapse. In paper III, we found that 8% of patients with grade 1-2 endometrioid 
endometrial carcinoma express low levels of ASRGL1. It would be interesting to 
explore if these patients could benefit from more extensive treatment. Conversely, 
adjuvant chemotherapy often results in damaging side-effects and reduced quality of 
life - especially in elderly and co-morbid patients. Biomarkers identifying patients 
who do not benefit from additional treatment may both improve these patients quality 
of life and reduce overall medical costs. We observed that high expression of 
ASRGL1 was associated with a favourable prognosis, and one could speculate that 
ASRGL1 may identify patients that could be spared from adjuvant chemotherapy. 




Evaluation of mRNA expression may be an alternative approach for assessment of 
prognosis in gene-based studies. Previously, reduced ASRGL1 gene expression has 
been reported as part of a 29 gene signature identifying a cluster of endometrial 
carcinomas with aggressive disease and poor recurrence-free survival (195, 196). 
ASRGL1 has also been identified as one of the 145 most differentially expressed 
genes between endometrioid and non-endometrioid endometrial carcinoma (197). In 
that study, ASRGL1 expression was downregulated in non-endometrioid compared to 
endometrioid cases, reflecting that low ASRGL1 is related to aggressive disease. 
Additionally, gene expression data from the TCGA study has demonstrated that 
patients with low ASRGL1 mRNA levels in their tumors have significantly worse 
overall survival compared to patients with high ASRGL1 expression levels (198). This 
supports our findings in paper III where low ASRGL1 mRNA expression is 
significantly associated with poor disease specific survival. We also find that 
ASRGL1 mRNA is significantly correlated with ASRGL1 protein expression, 
suggesting that both gene- and protein expression is lost as tumors dedifferentiate.   
 
5.2.5 ASRGL1 expression in metastatic lesions 
Metastatic disease is estimated to be the cause of up to 90% of cancer related deaths 
(199), and more research focusing on metastasizing tumors is needed. In paper III 
we observed that most patients with low ASRGL1 expression in their primary tumors 
also had low ASRGL1 expressing metastases. Heterogeneous expression of proteins 
is often observed between different metastatic lesions within the same individual, as 
reported for hormone receptors (200). Interestingly, when evaluating available 
metastatic lesions and corresponding primary tumors we found that most patients 
with multiple metastases had similar ASRGL1 expression in all lesions. We are the 
first to describe ASRGL1 expression in metastatic endometrial carcinoma. Our study 
includes sampled metastatic lesions with available corresponding primary tumors. 
The ability to evaluate ASRGL1 staining in paired primary tumors and metastases is 
a major advantage, as it may add relevant information on biomarker expression 
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during disease progression. Although based on metastases available for sampling, 
which may not be fully representative to all metastatic lesions, our findings are 
interesting and could be explored in future studies to evaluate the clinical importance 
of ASRGL1 expression in a metastatic setting.  
 
5.2.6 What is the functional role of ASRGL1 in endometrial 
cancer? 
ASRGL1 was first described as a protein that shares 77% of its genetic sequence with 
a rat sperm autoantigen (201), and it is classified as an enzyme in the N-terminal 
nucleophile hydrolase family (202). ASRGL1 is demonstrated to have both ʟ-
asparaginase and -aspartyl peptidase activity in vitro (202), but the knowledge 
concerning the functional role of ASRGL1 in normal and cancerous tissue is limited. 
Considering the above mentioned mechanisms one could speculate that loss of 
ASRGL1 function could promote cancer by leading to elevated cellular asparagine 
levels (which is reported to suppress apoptosis (203)) as well as accumulation of 
dysfunctional proteins due to reduced degradation of isoaspartyl peptides by -
aspartyl peptidases (202, 204).   
 
In some types of cancer, including breast, ovarian and cervical cancer, high levels of 
ASRGL1 in tumor compared to normal tissue are suggested to associate with poor 
prognosis and increased cell growth in vitro  (205-207). This is inconsistent with our 
findings, where low ASRGL1 protein expression is associated with aggressive 
disease and poor survival. The reason for these contrasting results is not known. 
However, we have evaluated ASRGL1 staining in precursor lesions and tumor tissue, 
and the expression of ASRGL1 in adjacent normal tissue in our patient cohort has not 
been assessed. Additionally, as the biological function of ASRGL1 in endometrial 
carcinoma has not been explored, it is likely that the observed differences in 
ASRGL1 expression between these cancers is caused by involvement of different 
molecular processes.  
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ASRGL1 is reported to display ʟ-asparaginase activity (202). ʟ-asparaginase has been 
used in the treatment of acute lymphoblastic leukemia (ALL) and Non-Hodgkin 
lymphoma for several decades. This has resulted in increased remission rates and 
survival - especially in children with ALL (208). The therapeutic potential of ʟ-
asparaginase is being explored in several solid tumors, including ovarian cancer and 
pancreatic adenocarcinoma (209-212). The rationale for treating endometrial 
carcinoma patients with ʟ-asparaginase might not be the same as for ALL, as ALL 
tumor cells are unable to synthesize asparagine and thus depend on the extracellular 
supply of asparagine (208). Still, it is tempting to speculate in a potential treatment 
effect also for endometrial carcinoma patients. By administering ʟ-asparaginase to 
patients with low ASRGL1 expression one may hypothesize that asparagine levels 
are reduced, thus minimizing its anti-apoptotic effects. ʟ-Asparaginase treatment in 
endometrial carcinoma should be further explored through both in vivo and in vitro 




Overall, this PhD project has focused on molecular biomarkers and orthotopic mouse 
models of endometrial carcinoma. We have developed orthotopical mouse models 
and advanced imaging protocols that enables in vivo studies of tumor biology, 
biomarkers and therapeutic strategies. We have also studied the promising prognostic 
biomarker ASRGL1 in both pre-and postoperative samples. 
 
 
Paper I: Orthotopic endometrial carcinoma mouse models are successfully 
established, both from a luciferase positive cell line and from patient-derived primary 
tumor cells. The small animal imaging modalities BLI, MRI, 18F-FDG PET/CT, and 
18F-FLT PET/CT all enable detection and monitoring of tumor progression in the cell 
line based mouse model. Additionally, PET/CT imaging (using both tracers) is well 
suitable for visualization of uterine tumor in PDX-models.  
 
 
Paper II: EpCAM is highly expressed in endometrial carcinoma cell lines and 
primary tumor tissue. EpCAM-AF680 NIRF imaging enables earlier detection of 
metastatic lesions compared to BLI in cell line based models of endometrial 
carcinoma, and is superior to 18F-FDG PET/CT in visualization of uterine PDX 
tumors. EpCAM-AF680 NIRF also enables in vivo evaluation of therapeutic response 
in orthotopic endometrial carcinoma PDX models.  
 
 
Paper III: ASRGL1 validates as a strong post-operative prognostic biomarker in 
endometrial carcinoma. Loss of ASRGL1 in hysterectomy samples is associated with 
aggressive disease and has independent prognostic value both in the whole patient 
population and in the endometrioid subgroup. ASRGL1 expression in endometrial 
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carcinoma metastases is also investigated for the first time, and is found to be low in 
the majority of metastatic lesions.  
 
 
Paper IV: Low ASRGL1 expression in curettage is a promising pre-operative 
biomarker for aggressive endometrial carcinoma, and has independent prognostic 
value both in the whole population and in the subgroup of patients with assumed low 
risk curettage histology. Low expression of ASRGL1 in pre-operative samples 
independently predicts lymph node metastasis, and may potentially be used to 




7. Future aspects 
Further improving endometrial carcinoma mouse models 
In paper I and II we successfully developed orthotopic PDX models of endometrial 
carcinoma; however, further refinement may improve the feasibility of these models 
for use in preclinical studies. A strategy using organoid cultures for xenografting is 
suggested to improve the efficiency of PDX engraftment whilst simultaneously 
reducing the time of expansion (213), and would facilitate experimental evaluation of 
both biomarkers and targeted therapies in a highly clinically relevant systemic setting. 
Future work with endometrial carcinoma PDX models should also include thorough 
characterization of morphological, histological and genomic features to determine the 
degree of genetic and phenotypic drift from the human donor tumor throughout the 
following passages in mice. 
 
The orthotopic PDX 4 model (Grade 3 endometrioid endometrial carcinoma, paper 
II) should be utilized in future studies of treatment response and drug resistance, 
preferably to explore biomarker-guided targeted therapies that may be clinically 
relevant for tumors with similar characteristics as this model. It would also be 
interesting to perform gene expression analyses of samples that were collected in the 
treatment study in paper II in order to elucidate potential mechanisms associated 
with paclitaxel and trastuzumab resistance. To improve the translational value of 
preclinical studies, validation of findings (both in the current and future experiments) 
should be performed in several different PDX models. However, establishment of 
such models is difficult, time-consuming and expensive. Collaboration with other 
institutions to assemble larger cohorts of PDX-models may provide a more robust 
platform for preclinical studies of biomarkers and therapies (171), and should be 
pursued in the future.  
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The future of preclinical imaging  
The infrastructure of preclinical small animal imaging is well developed in Bergen, 
thus allowing us to explore multimodal imaging approaches. However, this is not the 
case in many other centres. For research facilities that have to rely on only one 
imaging modality, optical imaging is an excellent alternative. In paper I and II we 
explored several small imaging modalities. However, much research is needed to 
determine which method (or combination of methods) is most optimal for imaging in 
the different endometrial carcinoma models. MRI is often applied as part of the pre-
operative diagnosis in endometrial carcinoma, and it would be interesting to evaluate 
the performance of MRI in imaging of orthotopic endometrial carcinoma PDX 
models - including monitoring of treatment. MRI has excellent soft tissue contrast, 
and in the future PET/MRI may be a better option for anatomical and functional 
visualization of endometrial carcinoma models than PET/CT. Ultrasound is another 
clinically relevant modality that is highly feasible for imaging of soft tissues (121), 
and the ability of ultrasound to detect and monitor development of uterine tumor 
should be explored in our in vivo mouse models.  
 
In paper II we developed a protocol for EpCAM-AF680 NIRF imaging of orthotopic 
endometrial carcinoma in preclinical mouse models. NIRF imaging is feasible also in 
clinical settings, such as for intraoperative mapping of sentinel lymph nodes. NIRF 
probes specifically targeting tumor cells could help visualize tumor infiltrates and 
metastatic lesions in real-time during surgery, potentially improving tumor resection 
and/or reducing the amount of healthy tissue that is removed (214). NIRF imaging 
targeting EpCAM has been demonstrated to detect orthotopic tumors in cell-line 
based models of head and neck, breast and colorectal cancer, and EpCAM has been 
suggested as a multi-tumor target for image-guided surgery (215). As endometrial 
carcinoma primarily is a surgically treated disease, it would be interesting to explore 
if EpCAM-AF680 could be used for image-guided surgery also in this large patient 
group. This could initially be tested through preclinical mouse models. Future studies 
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should also include IHC evaluation of EpCAM expression in metastatic lesions, 
preferably in a large cohort of endometrial carcinoma patients. 
 
ASRGL1  
Thorough preclinical validation of potential biomarkers is crucial before proceeding 
to clinical trials, both to improve the success rate of translation from bench to bedside 
and to spare patients from unnecessary distress. Clinical trials should be conducted to 
assess the utility of ASRGL1 in hysterectomy specimen as a prognostic biomarker 
(paper III). We are the first to describe that ASRGL1 expression in pre-operative 
curettage independently predicts lymph node metastases (paper IV), and this should 
be validated in independent patient cohorts prior to clinical testing. Additionally, it 
would be interesting to explore the functional role of ASRGL1 in normal 
endometrium and endometrial carcinoma through in vitro, and potentially also in 
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Orthotopic endometrial cancer models provide a unique tool for studies of tumour growth
and metastatic spread. Novel preclinical imaging methods also have the potential to quan-
tify functional tumour characteristics in vivo, with potential relevance for monitoring
response to therapy.
Methods
After orthotopic injection with luc-expressing endometrial cancer cells, eleven mice devel-
oped disease detected by weekly bioluminescence imaging (BLI). In parallel the same mice
underwent positron emission tomography–computed tomography (PET-CT) and magnetic
resonance imaging (MRI) employing 18F-fluorodeoxyglocose (18F-FDG) or 18F- fluorothymi-
dine (18F-FLT) and contrast reagent, respectively. The mice were sacrificed when mori-
bund, and post-mortem examination included macroscopic and microscopic examination
for validation of growth of primary uterine tumours and metastases. PET-CT was also per-
formed on a patient derived model (PDX) generated from a patient with grade 3 endome-
trioid endometrial cancer.
Results
Increased BLI signal during tumour growth was accompanied by increasing metabolic
tumour volume (MTV) and increasing MTV x mean standard uptake value of the tumour
(SUVmean) in
18F-FDG and 18F-FLT PET-CT, and MRI conspicuously depicted the uterine
tumour. At necropsy 82% (9/11) of the mice developed metastases detected by the applied
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imaging methods. 18F-FDG PET proved to be a good imaging method for detection of
patient derived tumour tissue.
Conclusions
We demonstrate that all imaging modalities enable monitoring of tumour growth and meta-
static spread in an orthotopic mouse model of endometrial carcinoma. Both PET tracers,
18F-FDG and 18F-FLT, appear to be equally feasible for detecting tumour development and
represent, together with MRI, promising imaging tools for monitoring of patient-derived
xenograft (PDX) cancer models.
Introduction
Endometrial cancer is the most common pelvic gynaecologic malignancy in industrialized
countries, and the incidence is increasing [1]. Although about 75% of the patients are treated
with tumour confined to the uterine corpus, 15–20% recur [2]. In patients with distant metas-
tases or locally recurrent disease, the effect of the conventional systemic therapy is poor with
reported median survival ranging from 7–12 months [3]. Thus, there is an urgent need to
develop more efficient therapies for metastatic endometrial cancer.
Preclinical testing of drug efficacy has been reliant upon subcutaneously implanted tumours
originating from human cancer cell lines or tumour biopsies into immunodeficient rodents [4].
Also for endometrial cancer, subcutaneous xenograft models have long been employed to
explore effect of new treatments [5]. This model enables monitoring of tumour growth by
visual inspection and palpation to monitor tumour growth. However, the subcutaneous model
has important limitations including non-metastatic behaviour, thus lacking immediate rele-
vance for humans [6]. Orthotopic xenograft models, whereby molecularly defined cancer cell
lines or primary patient cells are surgically implanted into the organ of origin, induce disease
that more accurately reflect human metastatic patterns and response to therapeutics. Orthoto-
pic endometrial cancer models have been successfully developed [6–8]. This has provided a
valuable research platform for studies of molecular and cellular mechanisms underlying
tumour growth and metastatic spread in endometrial cancer [8–13].
A challenge in such models is still to accurately determine tumour growth and drug efficacy
longitudinally. Bioluminescence imaging (BLI) represents one such useful preclinical imaging
method for in vivomonitoring of tumour growth and metastases in endometrial cancer xeno-
graft models from human cell lines, but requires that these are transfected with luciferase gene
[8, 9, 13]. Patient derived tumour xenograft (PDX) models, which better mimic the corre-
sponding human lesion and tumour growth (i.e. molecular type, stromal tissue interaction and
three dimensional growth in relevant organ) represent a more reliable tool to predict response
to chemotherapy [4]. Although methods are available to genetically manipulate PDX models
ex vivo, such manipulation cause irreversible genetic changes distancing the models from the
parental tumours [14]. BLI is therefore not an optimal method for PDX models [15]. Thus,
additional in vivo preclinical imaging methods to identify and quantify orthotopic endometrial
cancer xenograft progression and response to therapy, needs to be better explored to fully
exploit orthotopic PDX endometrial cancer models.
Preclinical positron emission tomography-computed tomography (PET-CT) and magnetic
resonance imaging (MRI) provide both anatomical and functional information from tumour
tissue [15, 16]. These novel imaging methods have been shown to predict response to therapy
Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma
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in various xenografts models [16] such as in colorectal cancer [17] (based on 18F-FLT and
18F-FDG PET), breast cancer [18] (dynamic contrast-enhanced (DCE)-MRI and diffusion
weighted imaging (DWI)) and in Ewing sarcoma [19] (whole body MRI and DWI). Character-
istics for PET-CT or MRI findings in endometrial cancer orthotopic mouse models have not
yet been reported, hence the feasibility of these novel imaging methods in monitoring tumour
progression and metastatic spread in this setting is largely unknown.
This study presents characteristic preclinical imaging findings for in vivo BLI, PET-CT
(with 18F-FDG and 18F-FLT) and MRI during tumour progression and metastatic spread in an
orthotopic endometrial cancer model. These observed in vivo imaging findings are also related
to the ex vivo BLI findings of single organs at necropsy and to histological characteristics for
the corresponding tumour tissue.
Material and Methods
Ethics statement
For patient samples and information, all parts of the study have been approved according to
Norwegian legislation, including the Norwegian Data Inspectorate, Norwegian Social Sciences
Data Services, and the Western Regional Committee for Medical and Health Research Ethics,
(NSD15501; REK 052.01). Participants gave written informed consent. All animal studies were
approved by the Norwegian State Commission for Laboratory Animals (ID 4036) and per-
formed according to the European Convention for the Protection of Vertebrates Used for Sci-
entific Purposes.
Cell lines and Retroviral transfection
The human endometrial cancer cell line Ishikawa was obtained from Sigma-Aldrich
(St. Louise, MO, USA) and the cell authenticity was confirmed by Short Tandem Repeat (STR)
profiling (IdentiCell, Denmark). Cells were kept in Minimal Essential Medium (MEM; Lonza,
Basel, Switzerland) supplemented with 5% heat-inactivated Fetal Calf Serum (FCS; Sigma-
Aldrich, St. Louis, MO, USA), 2 mM L-glutamine (Lonza, Basel, Switzerland), 1% non-essential
amino acids (Lonza, Basel, Switzerland), penicillin 100 IU/ml and 100 μg/ml streptomycin
(Lonza, Basel, Switzerland) at 37°C in a humidified atmosphere with 5% CO2. Ishikawa cells
were stably transfected using retroviral infection as described previously [20, 21] using the
luciferase expressing construct L192, combined with the tetracycline-regulated transactivator
(tTA). Stably transfected IshikawaLuc cells were selected with 1 μg/ml puromycine (Sigma-
Aldrich, St. Louis, MO, USA) and luciferase expression was confirmed by adding 2.5 mg/ml D-
luciferin (Promega, Madison, WI, USA) before ex vivo optical imaging.
Orthotopic endometrial cancer model
NOD-scid IL2Rgammanull (NSG) mice were originally a gift from Prof. Leonard D Schultz at
The Jackson Laboratory (Maine, USA) and bred at the Vivarium, University of Bergen, Nor-
way. Female 6–8 weeks old were maintained under pathogen-free conditions with food and
water provided ad libidum. Animals were kept on a 12 hours dark/night schedule at a constant
temperature of 21°C and at 50% relative humidity. Prior to surgery animals received 0.1 mg/kg
Buprenorphine hydrochloride (Temgesic, Reckitt Benckiser, Berkshire, UK) intramuscular, for
analgesia. Mice were anaesthetised with 250 mg/kg tribromoethanol (Sigma-Aldrich, St. Louis,
MO, USA) diluted in 2 methyl-2 butanol (Sigma-Aldrich, St. Louis, MO, USA) and placed on a
heating pad in dorsal decubitus. Fur on the abdomen was clipped and skin disinfected with sur-
gical iodine and 70% ethanol. A 1cm middle line incision was made in the lower abdomen
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(skin and muscles). The left uterine horn was exteriorized and 1x106 of IshikawaLuc cells resus-
pended in 50 μl of Matrigel (BDMatrigel Basement Membrane Matrix, BD Biosciences, San
Jose, CA) were injected directly into the endometrial cavity through the myometrium. A
0.3mm insulin syringe (Omnican 50, B-Braun, Melsungen, Germany) was used for the injec-
tion. The uterine horn was put back in the original position before muscles and skin was closed
with 5–0 absorbable sutures. After the surgery the animals were placed in a warm environment
and supervised until full recovery.
Generation and maintenance of patient derived xenograft (PDX) model
A biopsy from the primary tumour of a 69 year old woman diagnosed with grade 3 endome-
trioid endometrial cancer was placed on ice until processing. Tissue was mechanically dissoci-
ated using sterile scalpels and sequentially filtered through a 40 μm pore filter (Fisher) and
centrifuged at 900rpm for 4 min. The cell pellet was resuspended in Matrigel and orthotopic
implantation in four mice was performed as described above. The mice (F1 generation) were
monitored closely for visible signs of disease development and examined using PET CT when
clinical signs of disease were presented. Mice were thereafter sacrificed, and a cell suspension
from the primary tumour was prepared and implanted in the next generation of mice (F2).
Samples for histological examination of tumour grade and type were taken in parallel. The new
generation was monitored in a similar manner until presenting clinical signs of disease, when
PET CT was performed. The mouse model is continuously rederived following the same
protocol.
Experimental set-up for multimodal imaging
Optical imaging. In total 15 mice were orthotopically injected with IshikawaLuc cells. All
mice were subjected to weekly examination by bioluminescence to follow tumour growth and
metastatic dissemination. Mice were injected intraperitoneally (i.p.) with D-luciferin (150 mg/kg)
and anaesthetised with 3% isoflurane (Isoba Vet, Schering-Plough, Brussel, Belgium) 10 minutes
before optical imaging using an In-Vivo FX PROmolecular imaging system (CarestreamHealth,
Inc., Rochester, NY, USA). Total bioluminescence values were measured using manual Region of
interest (ROI) of the whole abdomen using the CarestreamMI software (Standard Edition,
v.5.0.6.20, Carestream Health, Inc.). Three mice showed no BLI signal after four weeks, suggest-
ing no tumour development in the uterus, possibly due to vaginal leakage of cells after surgery.
One mouse died during anaesthesia for PET scan. These four mice were excluded from the exper-
iment. The 11 remaining mice were monitored weekly and euthanized when moribund as
defined by weight loss 10–15%, lethargy or ruffled fur. Ten minutes before necropsy, all mice
were injected i.p. with D-Luciferin and organs were imaged ex vivo for evaluation of disease dis-
semination using Optix MX3 Small Animal Molecular Imager (ART Inc., Saint-Laurent, QC,
Canada) supplied with Optix Optiview software. After BLI imaging, the tissue biopsies were fixed
in 4% buffered formalin and embedded in paraffin before they were processed for histological
analysis.
PET-CT. PET-CT was performed in all mice weekly from week 5/6–week 7/8 after injection
of IshikawaLuc cells. In one of the mice PET-CT was also performed 12 and 13 weeks after Ishika-
waLuc cells injection. The PET-CT scans consisted of 18F-FLT PET only (n = 2), 18F-FDG-PET
only (n = 3) or both 18F-FLT PET and 18F-FDG PET (n = 6). The last PET-CT examinations
were performed 7 days (n = 1), 11 days (n = 3), 18 days (n = 1), 35 days (n = 2) and 49 days
(n = 4) respectively before the mice were sacrificed, respectively. This approach was chosen in
order to reduce the cost of the experiments as well as to minimize stress for individual animals
also undergoing weekly BLI. For mice with slow tumour progression limited capacity of the
Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma
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PET-scanner precluded PET scanning immediately prior to sacrifice. For the PDXmodel,
the PET-CT scans consisted of 18F-FLT PET in the F1 generation and 18F-FDG-PET in the F2
generation. PET-CT scans were performed using the integrated PET-CT scanner nanoScan PC
PET/CT (Mediso Medical Imaging Systems Ltd, Budapest, Hungary) featuring spatial resolu-
tions of 800 μm and 30 μm of the respective PET- and CT detector systems. The PET field of
view (FOV) was 9.5 x 8 cm in axial and transaxial directions allowing whole-body imaging of
mice. The PET detectors consist of LYSO crystals, and acquisition was performed in 1:5 coinci-
dence and normal count mode. Mice were scanned simultaneously without prior fasting using a
dual mouse bed with integrated system for anaesthesia and heating. Animals were anaesthetised
using 3% sevoflurane (Sevoflo, Abbott, Illinois, USA) and 18F-FDG (mean dose of 7.3 +/-1.6
MBq) was injected via the tail vein 30 seconds after the start of the PET scanning. Total scan
time was 60 minutes, and the last 30 minutes was reconstructed into a static image. For 18F-FLT
PET-CTmice were anesthetised and 18F-FLT (mean dose of 7.4+/-2.3 MBq) was injected via the
tail vein 30 minutes prior to scanning. PET acquisition time was 30 minutes. For both tracers, a
whole-body CT scan (helical projections with tube energy of 50 kvP, exposure time 300 ms, 720
projections, max FOV, binning 1:4) was performed for anatomical information and attenuation
correction of PET images.
Reconstruction and post-processing of PET-CT data. The PET images were recon-
structed using the supplier’s reconstruction algorithm Tera-Tomo 3D (OSEM), with correc-
tions for depth-of-interaction (DOI), radionuclide decay, randoms, crystal dead time, detector
normalization, and attenuation correction, and with a detector coincidence mode of 1:3, 4 iter-
ations and 6 subsets, no filtering. CT images were reconstructed using RamLak filter. The PET
and CT images were co-registered automatically. Images were reconstructed with a voxel size
of 0.25×0.25×0.25 mm3 for CT, and 0.4×0.4×0.4 mm3 for PET. Data analyses were performed
using InterView Fusion version 2.02.055.2010 (Mediso Ldt., Budapest, Hungary). For each
scan a spherical volume of interest (VOI) with radius 1.5 mm were drawn manually over the
muscles in the back of the neck. Standard uptake value (SUV) was calculated using the equa-
tion: SUV = CPET(T)/(ID/BW), where CPET(T) is the measured activity in tissue, ID is injected
dose measured in kBq, and BW is mouse body weight in kg. SUVmean is the SUV mean value of
all voxels included in the VOI. SUVmean in this nuchal muscle was used as a reference tissue in
order to enable segmentation of putative tumour tissue having SUV ratios (SUVR) of>2 and
>6 for 18F-FLT and 18F-FDG, respectively. VOIs of primary uterine tumours and of likely
metastases were drawn semi-automatically in the PET images for estimation of metabolic
tumour volumes (MTV) and their corresponding SUVmean. The parameter Total Lesion Gly-
colysis (TLG) in the tumour was calculated based on the 18F-FDG PET-CT scans using the
following equation: TLG = FDG-SUVmean x MTV [22]. For the
18F-FLT PET-CT scans a simi-
lar parameter was calculated based on the same equation and named FLT-SUVmean x MTV.
MRI. MRI was performed in one mouse at week 11 after injection of IshikawaLuc cells
(3 weeks before sacrifice). The MRI scan was performed on a 7T horizontal-bore preclinical
scanner (Pharmascan 70/16, Bruker Corporation, Germany), using a 40 mm ID mouse body
quadrature volume resonator in a single-coil (TX/RX) configuration. During scanning, the
mouse was anesthetized using 3.0% sevoflurane. Respiration rate and body temperature were
monitored and kept constant at 60±20 respiratory cycles/min and 37+/-2°C, respectively. For
identification of tumour and estimation of tumour size, a T2-weighted rapid acquisition with
relaxation enhancement (RARE) sequence (TE/TR = 36/4300 ms, 2 averages, matrix 256x256,
field of view (FOV) 3.2 x 3.2 cm, slice thickness 1 mm) and pre- and a post-contrast T1-weighted
RARE sequences (TE/TR = 9/1000 ms, 4 averages, matrix 256x256, FOV 3.2 x 3.2 cm, slice thick-
ness 1 mm) were employed. The post-contrast images were collected after intravenous tail-vein
injection of Gd-based contrast agent (Dotarem, Guerbet USA, volume 30uL, dose 0.1 mmol/kg
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of body weight). In addition, apparent diffusion coefficient (ADC) maps were generated from
diffusion-weighted EPI images (DWI) (TE/TR = 24.6/3100 ms, 2 averages, matrix 128x128,
FOV 3.2 x 3.2 cm, slice thickness 1 mm and 3 diffusion directions with b-values of 100, 200, 400,
600, 800, 1000 s/mm2).
Histological examination and Immunohistochemical (IHC) analysis
Formalin-fixed tissue was processed for routine histological examination. 4 μm sections were
stained with Hematoxylin–Eosin (HE) and examined by a pathologist (NCMV) for typing and
grading of the tumours. To verify presence of human cells, IHC staining was performed on full
section to detect expression of human ERα. Briefly, sections were dewaxed with xylene, rehy-
drated in graded ethanol before microwave antigen retrieval, and stained for 60 min in room
temperature for human ERα expression using 1:400 HC-20 (Santa Cruz Biotechnology, Dallas,
TX, USA) or 1:400 Clone SP1 (Thermo Scientific, Fremont, CA, USA). Anti-rabbit secondary
antibody (Dako, Denmark) was applied for 30 minutes, followed by 8 minutes with Diamino-
benzidine (DAB+, Dako, Denmark) before counterstaining with hematoxylin. To verify the
species specific nature of the antibody, sections were compared to the non-species specific anti-
body from Santa Cruz (S1 Fig), validating that the human specific antibody only detected ERα
in cells of human origin.
Results
IshikawaLuc cells form primary endometrial cancers in mice
We developed an orthotopic mouse model that can be monitored by bioluminescence. Mice
were monitored for up to 13 weeks and sacrificed when reaching humane endpoint. Body
weight was monitored weekly (Fig 1A). A clear reduction in body weight was observed as the
BLI signal increased. At 13 weeks post injection, all mice had reached a moribund disease
condition (Fig 1B).
Fig 1. Orthotopic injection of IshikawaLuc cells results in weight loss and reduced survival.Mice injected with IshikawaLuc cells were monitored weekly
for signs of disease development. Weight loss (A) was detected as an early sign of disease. Mice developing symptoms of severe disease were sacrificed
and the overall survival is visualized in a Kaplan-Meier survival plot (B).
doi:10.1371/journal.pone.0135220.g001
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Bioluminescence monitoring of tumour growth
A bioluminescence signal restricted to the uterine area was observed the first weeks, followed
by more diffuse abdominal signal as the tumour burden was increasing and the mice developed
metastatic disease. The total BLI signal increased dramatically the last weeks before the animals
were sacrificed (Fig 2A and 2B).
Two mice showed no signs of metastatic spread but had large tumours limited to the uterus
when sacrificed. The remaining nine mice had all developed advanced disease with metastatic
spread and variable amounts of ascites. After macroscopic post-mortem examination, organs
were imaged ex vivo to detect tumour cell dissemination (Fig 2C, Table 1). A strong BLI signal
was observed in the uterus of all animals. Increased BLI signal was observed in the ovaries
(n = 4), pancreas (n = 7), kidney (n = 2), spleen (n = 3), liver (n = 6) and lung (n = 4) as well as
in connective tissue surrounding the uterus (n = 9). Nodules suspected to be metastatic lymph
nodes were also BLI positive (n = 4). No BLI signal was detected in the adrenal glands.
Histological evaluation of the model
The histology of the primary tumour and presence of metastatic spread were determined on
HE stained sections (Fig 3). Histological evaluation of the organs revealed normal histology
Fig 2. Tumour growth monitored by Bioluminescence Imaging (BLI). Tumour growth was monitored weekly by in vivo BLI and an increase in the net
bioluminescence versus time was observed (A, B). Organs were also examined by BLI post-mortem to visualize metastatic spread (C). Strong BLI signals
were detected at site of injection (left uterine horn; luh), right ovary (o), connective tissue surrounding the uterine horn (ct), pancreas (p) and metastatic node
(mn). Spot signals were detected in the liver (l), spleen (s), kidneys (k), heart (h) and lung (lu). No signal was detected in adrenal gland (a).
doi:10.1371/journal.pone.0135220.g002
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with intact endometrial glands in the right uterine horn. A solid growing primary tumour was
detected in the left uterine horn (at site of injection; Fig 3A) with characteristics of a grade
3 endometrioid endometrial cancer (Fig 3B), and areas of necrosis and myometrial invasion.
Metastases to the ovaries (Fig 3C) were mostly solid with necrotic areas, but gland formation
was also detectable in some cases. No remaining lymph node tissue was detected in metastatic
nodes (Fig 3D). Larger separately growing tumour fragments were detected in the pancreas
(Fig 3E). BLI positive kidneys and spleens had tumour cells in the outer surface of the organ,
with no invasion of the parenchyma. This was also true for three BLI positive liver biopsies
(Fig 3F). All mice with cancer cells detected in the outer lining of organs had ascites. Diffuse
small tumour nodules were found in vessels in the lungs (Fig 3G), also in two lung biopsies that
appeared negative in the BLI imaging (Table 1).
Cellular protein expression of human ERα was verified in human cells (S2 Fig). We found
heterogeneous expression of ERα in the primary tumour, also showing myometrial infiltration
(S2A Fig), consistent with reports that Ishikawa cells are ERα positive but with a tendency to
lose expression of ERα with dedifferentiation. We also clearly identified presence of metastatic
IshikawaLuc cells in pancreatic tissue (S2B Fig), in the capsule of the liver (S2C Fig) and in the
vessels in pulmonary tissue (S2D Fig).
PET-CT monitoring of tumour progression
Evident 18F-FDG/18F-FLT-avid tumour tissue in the uterus (Fig 4A and 4B and Fig 5C and 5D)
was observed in 6 out of 7 mice, which were scanned 35 days prior to sacrifice. The remain-
ing mice (n = 4) showed no visible tumour at their last PET-CT scans, 49 days prior to sacrifice.
However, these mice did develop tumour growth and metastases at a later point with increased
BLI tumour signal after their last PET-CT scans.
In the mice having weekly PET-CT scans the last weeks before sacrifice, increasing MTV
and SUVmean x MTV was observed in both primary tumours (Fig 4A and 4C–4F) and metasta-
ses (Fig 4B and 4G–4J). The highly 18F-FDG/18F-FLT- avid tissue (Fig 4A and 4B), assumed to
represent tumours, was histologically confirmed as primary malignant uterine tumours (Fig
4K) and metastases (Fig 4L), respectively, at necropsy. Although the absolute values for
Table 1. Tumour development andmetastasis dissemination in IshikawaLucmodel. Total number of
mice with organs affected by disease, defined by positive BLI signal and presence of cancer cells in histologic
sections.
Organ affected: BLI (%) Histology (%)
Uterus 11 (100) 11 (100)
Mice with metastases 9 (82) 9 (82)
Ascites 8 (73) NA
Lymph nodes 4 (36) 4 (36)
Ovaries 4 (36) 4 (36)
Liver 7 (64) 4 (36)
Lungs 4 (36) 6 (55)
Connective tissue 9 (82) 9 (82)
Pancreas 7 (64) 7 (64)
Spleen 3 (27) 0
Kidneys 2 (18) 0
Adrenal glands 0 (0) 0 (0)
NA: Not applicable.
doi:10.1371/journal.pone.0135220.t001
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Fig 3. Histological evaluations of tumour characteristics and spread of disease.Organs were fixed in
formaldehyde, sectioned and stained with HE to confirm presence of tumour tissue and for histological
characterization of tumour. Sections from a representative mouse depict a large tumour mass in the left
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calculated MTV and SUVmean x MTV of the tumours using different tracers on PET-CT were
not directly comparable, both tracers seemed equally feasible to depict tumour tissue and mon-
itoring tumour growth and metastatic spread at PET-CT (Fig 4A and 4B and Fig 5C and 5D).
MRI of tumour model
MRI conspicuously depicted the boundaries of the uterine tumour (Fig 5A). The tumour was
hyperintense on T2-weigthed images and moderately contrast-enhancing on T1-weighted
uterine horn (A) with necrotic tissue in the centre. Normal uterine morphology is seen in the right uterine horn
with endometrial glands and normal stroma and myometrium. Detail of tumour in the left uterine horn (B)
reveals solid growing tumour, resembling a grade 3 endometrioid endometrial cancer. Solid tumour masses
were also detected in ovaries (C). Inguinal lymph node, macroscopically suspected to be metastatic, was
confirmed to represent a metastasis (D), however, without visible surrounding lymphoid tissue. Solid tumour
components are depicted in the pancreas (E) with tumour tissue infiltrating surrounding fat tissue. Metastasis
is observed on the outer surface of the liver (F), and tumour tissue is also detected in blood vessels of the
lung (G), the latter indicating hematogenous spread.
doi:10.1371/journal.pone.0135220.g003
Fig 4. Tumour growth monitored by PET-CT. Tumour growth in the left uterine horn (A) and growth of abdominal metastasis (B) measured by 18F-FLT
PET-CT at 5, 6 and 7 weeks after inoculation of cells; and by 18F-FDG PET-CT 8 weeks after inoculation (A and B) in the samemouse. Estimated metabolic
tumour volume increased from 5 to 7 weeks after inoculation based on 18F-FLT PET-CT but was stable or slightly decreased from 7 to 8 weeks after
inoculation based on 18F-FLT PET-CT (week 7) and 18F-FDG PET-CT (week 8) (C/D, G/H). The estimated 18F-FLT-SUVmean x MTV steadily increased from
5 to 7 weeks after inoculation in both the primary tumour (E) and in the metastasis (I). Panel F and J show Total Lesion Glycolysis (18F-FDG-SUVmean x MTV)
for primary tumor and metastasis, respectively. Histologic examination of the uterus (K) and the pancreas (L) validated presence of malignant tissue
(asterisks) as detected with PET-CT.
doi:10.1371/journal.pone.0135220.g004
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series after i.v. contrast. Restricted diffusion within the tumour tissue was striking with hyper-
intensity on high b-value images and corresponding low ADC value on the ADC map (Fig 5A).
The PET-CT and MRI findings of the IshikawaLuc cell model are similar
to patterns detected for human endometrial cancers
The uterine tumours in the mice were highly 18F-FDG-avid (Figs 4A and 4B and 5C), thus resem-
bling the metabolic behaviour of the human endometrial cancers, which also typically exhibit
marked 18F-FDG-avidity (S3A, S3E Fig). Both in patients and in the preclinical model, the tumour
is hyperintense on T2-weighted images (Fig 5A and S3C, S3F Fig) and moderately contrast-
enhancing on T1-weighted images after intravenous contrast (Fig 5A and S3D Fig). Similarly, the
restricted diffusion observed within the tumour in the mouse model (with measured tumour
ADC value of 1.11 x 10−3mm2/s; Fig 5A) is quite similar to that in endometrial cancer tissue in
patients (S3G and S3H Fig; tumour ADC value in this patient was 0.83 x 10−3mm2/s).
Fig 5. Multimodal imaging of the samemouse by MRI, 18F-FDG PET, 18F-FLT PET and BLI.MRI three weeks presacrificed (A) depicting large uterine
tumour tissue in the left uterine horn (thin arrows) with intrauterine fluid cranial of the tumour (filled large arrow) and small amounts of free intraperitoneal fluid
cranial to the right kidney (K) (small arrows). The tumour tissue is moderately enhancing on T1-weighted series after contrast and the tumour exhibits
restricted diffusion with hyperintensity on high b-value DWI with corresponding low apparent diffusion coefficient (ADC) value (1.11 x 10−3mm2/s) on the
ADCmap (A). BLI 4 to 1 weeks presacrificed (B) shows increasing BLI signal corresponding to the tumour of the left uterine horn; the corresponding tumour
tissue was evident macroscopically and confirmed microscopically at necropsy (B). 18F-FDG PET-CT two weeks presacrificed (C) depicts a large 18F-FDG-
avid tumour in the left uterine horn (arrows) with estimated metabolic tumour volume of 33 ml. 18F-FLT PET-CT one week presacrificed (D) depicts large
18F-FLT-avid tumour in the left uterine horn (arrows) with estimated metabolic tumour volume of 44 ml. 18F-FDG/18F-FLT-avidity in a VOI in the nuchal
muscular tissue (C and D; small arrows) was used as reference tissue to define a threshold for likely tumour tissue (activity of x2 and of x6 for 18F-FLT and
18F-FDG, respectively) to be included in the estimated metabolic tumour volume. B: bladder; H: heart.
doi:10.1371/journal.pone.0135220.g005
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PET-CT represents a powerful tool for detection of tumour tissue in PDX
model of endometrial cancer
Although orthotopic models generated from established cell lines develop tumours in the
uterus, a PDX model is likely to better mimic the clinical setting relevant for disease spread and
response to therapy. This PDX model was developed from a patient primary tumour (Fig 6A)
with grade 3, endometrioid endometrial type. Histologic examination of the primary tumours
of both the F1 (Fig 6B) and the F2 (Fig 6C) generation reveal high resemblance to the donors,
and both were classified as grade 3 endometrioid, endometrial cancers by the pathologist.
PET-CT was successfully used to detect tumour growth using 18F-FLT in generation F1 (not
shown) and 18F-FDG in generation F2 (Fig 6D). Highly 18F-FDG-avid tumour tissue in the
uterine fundus and both the left and the right uterine horn was macroscopically verified to rep-
resent tumour tissue (Fig 6E).
Fig 6. 18F-FDG PET detects tumour in an orthotopic endometrial cancer PDXmodel.Mice were
implanted in the uterus with cancer cells from a patient biopsy and rederived for two generations to develop a
PDXmodel. Histological examination revealed that both the F1 (B) and the F2 (C) mice developed tumours
closely resembling the parental tumour, defined as an endometrioid grade 3 endometrial cancer (A). 18F-FDG
PET was successfully used to detect tumour growth in both generation F1 (not shown) and generation F2 (D).
Highly 18F-FDG-avid tumour tissue (large arrows) in the uterine fundus (UF) and both the left and the right
uterine horn (LU, RU respectively) depicted at PET-CT (D). Macroscopic examination revealed a large
tumour infiltrating both the uterine horns as well as the bladder (E) and corresponded well with the tissue
detected as tumour by 18F-FDG PET. B, bladder; H, heart; K, kidney; LU, left uterine horn; RU, right uterine
horn; UF, uterine fundus.
doi:10.1371/journal.pone.0135220.g006
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Discussion
One major challenge in cancer research today is to what extent the cancer models mimic the
disease in a human setting. The use of mouse models has become increasingly popular, includ-
ing both sub-cutaneous and orthotopic models, in combination with cell line based and PDX
models [23]. The ability to monitor disease development and response to therapy, is of great
importance when choosing the model system, and several non-invasive imaging models are
presently available, although not extensively explored for uterine cancer. Still, many of these
are best suited for cell line based models since they ultimately rely on genetic engineering of the
cells. The availability of PET tracers and small scale imaging equipment for PET-CT and MRI
has improved our ability to study cancer development and metastatic spread without such use
of reporter genes [24]. This study, describing the typical imaging findings based on in vivo BLI
in parallel with PET-CT and MRI findings for the first time in an orthotopic endometrial can-
cer model, demonstrates an excellent feasibility of this multimodal imaging platform to moni-
tor tumour progression and metastatic spread.
We utilized the orthotopic IshikawaLUC model of endometrial cancer to trace tumour
growth using BLI and verified the methods ability to detect tumour growth and spread by mac-
roscopic and microscopic necropsy examination of affected organs. As reported previously by
others [7, 21, 25], BLI proved to be an effective imaging method for detection of tumour
growth and metastases, especially when combined with post mortem ex vivo BLI imaging of
organs. For growth of tumour cells in the peripheral margins of an organ, the in vivo BLI
method was not able to accurately detect the exact organ specific location of the signal and ex
vivo BLI or microscopic examination was necessary. In spite of these limitations, BLI is a pow-
erful imaging tool to monitor cancer cell line growth, however with limited value for monitor-
ing tumour growth in orthotopic PDX models. We therefor explored the same mice in parallel
by PET-CT and MRI to explore the potential for these methods to detect tumour development.
PET-CT was performed using two different tracers enabling imaging of different metabolic
properties of the tumour tissue. 18F-FLT is a nucleoside analogue that is taken up in proliferat-
ing cells in the S-phase. 18F-FLT enters cells via passive diffusion and active nucleoside trans-
porters. It undergoes phosphorylation by the enzyme thymidine kinase 1 (TK1) and is trapped
intracellularly [26]. The uptake of 18F-FLT is thus related to the metabolism of the nucleosides
and is considered a marker for cell proliferation [16]. 18F-FDG is a glucose analogue that tends
to accumulate in tissue with upregulated glucose transporter expression and/or increased meta-
bolic activity [16]. Most cancers show an increased aerobic glycolysis leading to an increased
uptake of 18F-FDG. Whereas 18F-FDG-avidity is nonspecific for tumour tissue, and a charac-
teristic also of inflammatory or infectious disease, 18F-FLT-avidity is believed to almost uni-
formly indicate presence of viable tumour cells [16]. Interestingly, both tracers seemed equally
feasible of depicting and monitoring tumour growth and metastatic dissemination in this
mouse model.
The uptake of both 18F-FDG and 18F-FLT in a tumour is considered to reflect tumour viable
cell densities, and the product SUVmean x MTV, referred to as Total Lesion Glycolysis when
using 18F-FDG as tracer, is thus a measure of the total number of viable tumour cells in the
tumour [22]. Interestingly, we observed a gradual increase in SUVmean x MTV prior to sacrifice
both in the primary tumour and in the metastasis (Fig 4E/4F and 4I/4J, respectively), whereas
estimated MTV in a mouse decreased in the primary tumour and was stable in the metastasis
at the last study when 18F-FDG replaced 18F-FLT (Fig 4C/4D and 4G/4H, respectively). A plau-
sible explanation of this finding regarding estimated MTV when using different tracers may be
differences in tracer characteristics for the same tumour, as well as the applied thresholds for
the two tracers to estimate MTV. Further studies are needed to establish optimal PET imaging
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parameters and PET tracers for reliable estimation of tumour burden and progression as well
as response to therapy in this mouse model.
The ability of PET-CT to validly detect and to monitor tumour growth quantitatively is
affected by various known factors such as tumour size, surrounding background activity, spa-
tial resolution of the PET-CT scanner and reconstruction algorithms of the scanner [27]. The
recorded spatial resolution of 800 μm and 30 μm for the respective PET- and CT detector sys-
tems of the PET-CT scanner in this study, would ideally allow detection of very small lesions
down to 0.8 mm. However, we found that early detection of the very small uterine tumours
and metastases were difficult due to radiotracer uptake in neighbouring organs i.e. the bladder
and kidneys and often also the intestines. However, when a gradual increase of radiotracer
activity was depicted in the uterus and at the same extrauterine sites on consecutive images
(suggesting metastases), the evidence of tumour growth seemed obvious, and the tissue of
increased tracer uptake was confirmed to represent tumours at the corresponding sites at
necropsy.
A limitation of this study is its ineligibility to compare the estimated MTV at PET to tumour
volumes based on necropsy, which would be highly interesting. Such a comparison would
allow an analysis of the optimal threshold for discriminating the tumour from the surrounding
tissue and for estimating the corresponding correct tumour volumes. However, in order to per-
form such a comparison meaningfully, the PET-CT should be performed immediately prior to
sacrifice. Since this was not done in the present study, we plan to do so in a follow-up study in
order to further refine and validate the MTV measurements based on PET-CT.
The imaging findings presented in this study during tumour growth and metastatic spread
apply to untreated mice. Future studies will thus be needed to explore the feasibility of the
same multimodal imaging platform to evaluate treatment response during therapy. However,
the ability to visualize and quantify the tumor burden before treatment is a prerequisite in
order to succeed in the evaluation of treatment response. Thus, we propose that the presented
findings in untreated mice make the same imaging methods very promising for evaluation of
treatment response, although this remains to be demonstrated in future studies. Furthermore,
including preclinical ultrasound scanning during tumor growth and therapy may represent an
intriguing addition to the multimodal imaging platform already explored in this study. Ultra-
sound may be especially translatable to the clinic, since patients with symptoms of endometrial
cancer are often subjected to vaginal ultrasound as primary imaging examination.
Interestingly, the functional tumour characteristics based on PET-CT and MRI are very
similar to that observed in human endometrial cancer, supporting a promising translational
relevance of this imaging integrated tumour model for assessing tumour growth. The findings
in this model derived from human endometrial cancer cell lines, as well as the PDX model,
open the avenue for further exploring the value of PET-CT and MRI in monitoring tumour
growth and metastatic spread in PDX models of endometrial cancer. This may prove highly
clinically relevant since PDX models are likely to have an increased translational relevance for
drug testing with relevance for a human tumour setting.
Conclusion
We have demonstrated the feasibility of a multimodal imaging platform using BLI, 18F-FDG
PET, 18F-FLT PET, and MRI to detect and monitor tumour progression in an orthotopic endo-
metrial cancer model derived from human cell lines. The latter three imaging methods are well
suited also in patients derived tumour models in which BLI is ineligible. PET-CT is also dem-
onstrated to detect tumour tissue in a PDX model. PET-CT and MRI may thus represent
Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma
PLOSONE | DOI:10.1371/journal.pone.0135220 August 7, 2015 14 / 17
powerful tools for monitoring tumour progression and functional changes for preclinical test-
ing of systemic therapy in orthotopic models more reliably mimicking human endometrial
cancer.
Supporting Information
S1 Fig. Identification of human specific anti-Estrogen Recetor α antibody. Immunohisto-
chemical staining was performed according to a standard protocol. Paraffin sections from
mouse uterus implanted with Ishikawa human endometrial cancer cells were stained with 1:50
anti-ERα (A; sc-543 Santa Cruz Biotechnologies) or 1:400 anti-ERα (B; SP1, Thermo) for
detection of endometrial cells expressing ERα. Both antibodies are raised in rabbit and selected
to avoid crossreaction with mouse immunoglobulins. The Santa Cruz antibody (A) was found
to detect both mouse and human ERα, while the Thermo antibody SP1(B) was human specific.
The SP1 antibody was selected to specifically detect localization and spread of implanted cells.
(PDF)
S2 Fig. Detection of metastatic spread by IHC staining for human ERα. To verify presence
of the ERα positive human IshikawaLuc cell line spread to distant organs, sections were stained
for expression of human Estrogen Receptor α. Myometrial tumour infiltration was detected in
the uterus (A) and metastases were detected in the pancreas (B), liver (C) and in the lungs (D);
for all tumour sites positive staining for human ERα confirming spread of the human tumour
cells.
(PDF)
S3 Fig. Example of human endometrial carcinoma assessed by preoperative imaging and
estrogen receptor staining in histological section. 18F-FDG PET-CT (A, E), CT (B),
T2-weighed (C, F) and contrast enhanced T1-weighed (D) MRI, diffusion weighted imaging
(b = 1000 s/mm2) (G) with corresponding apparent diffusion coefficient (ADC) map (H) and
positive immunohistochemical staining for estrogen receptor of the uterine tumour tissue (I)
from an 80-year old female with FIGO stage 2, endometrioid endometrial cancer. 18F-FDG
PET-CT shows a highly 18F-FDG-avid uterine tumour (A, E; arrows) with an estimated meta-
bolic tumour volume of 22 ml. The tumour is also conspicuously depicted at CT (B) and MRI
(C-D, F-H; arrows) exhibiting restricted diffusion on the ADC map (H) with tumour ADC
value of 0.83 x 10−3 mm2/s.
(PDF)
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H I G H L I G H T S
• ASRGL1 validates as a prognostic marker in a prospective setting.
• Low ASRGL1 protein and ASRGL1mRNA expression predicts poor outcome.
• ASRGL1 expression has independent impact on survival.
• Precursor lesions express high ASRGL1 levels.
• The majority of metastases have low ASRGL1 expression.
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Objective. Loss of Asparaginase-like protein 1 (ASRGL1) has been suggested as a prognostic biomarker in
endometrial carcinoma. Our objective was to validate this in a prospectively collected, independent patient
cohort, and evaluate ASRGL1 expression in endometrial carcinoma precursor lesion and metastases.
Methods. 782 primary endometrial carcinomas, 90 precursor lesions (complex atypical hyperplasia), and 179
metastases (from 87 patients) were evaluated for ASRGL1 expression by immunohistochemistry in relation to
clinical and histopathological data. ASRGL1 mRNA level was investigated in 237 primary tumors and related to
survival and ASRGL1 protein expression.
Results. Low expression of ASRGL1 protein and ASRGL1 mRNA predicted poor disease specific survival
(P b 0.001). Inmultivariate survival analyses ASRGL1 had independent prognostic value both in the whole patient
cohort (Hazard ratio (HR): 1.53, 95% confidence interval (CI): 1.04–2.26, P = 0.031) and within the endometrioid
subgroup (HR: 2.64, CI: 1.47–4.74, P=0.001). LowASRGL1 expressionwas less frequent in patientswith low grade
endometrioid primary tumors compared to high grade endometrioid and non-endometrioid primary tumors, and
ASRGL1 was lost in the majority of metastatic lesions.
Conclusions. In a prospective setting ASRGL1 validates as a strong prognostic biomarker in endometrial
carcinoma. Loss of ASRGL1 is associated with aggressive disease and poor survival, and is demonstrated for the
first time to have independent prognostic value in the entire endometrial carcinoma patient population.








Endometrial carcinoma is a malignancy originating in the female re-
productive tract, and is the fourth most diagnosed cancer in European
women after breast, colorectal and lung cancer [1]. Primary surgical
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treatment of endometrial carcinoma is curative for most patients, but
15–20% suffers a relapse within few years [2,3]. Prognosis for recurrent
endometrial carcinoma is often poor, especially in patients with systemic
recurrence [3]. Little improvement in treatment and survival has been
achieved over the last decades, highlighting the need of targeted thera-
pies andmore individualized cancer treatment [4]. Discovering, validating
and implementingnewbiomarkers that can identify high-risk endometri-
al carcinomapatients is crucial as suchmarkers canpotentially guide phy-
sicians planning treatment for individual patients [2]. Asparaginase-like
protein 1 (ASRGL1) is an enzyme classified as a N-terminal nucleophile
(Ntn) hydrolase, exhibiting both ʟ-asparaginase and β-aspartyl peptidase
activity [5]. It was first described as a novel protein sharing 77% of its ge-
netic sequence with a sperm autoantigen found in rats [6]. The role of
ASRGL1 in cancer development and progression is not clear. For several
malignancies including mammary, ovarian, and prostate cancer high
levels of ASRGL1 in tumor have been reported [7,8]. In endometrial carci-
noma loss of the gene encoding ASRGL1 has previously been reported as
part of a 29-gene signature associated with features of aggressive disease
and poor recurrence-free survival [9,10]. Loss of ASRGL1 in primary
endometrial carcinoma has also been suggested to be an independent
biomarker for disease-specific survival in a subgroup of patients with
endometrioid endometrial carcinoma [11]. In the present study we
aimed to validate ASRGL1 as a prognostic biomarker in endometrial carci-
noma, and to evaluate the expression of ASRGL1 in clinical specimens
from a large, prospectively collected patient cohort including precursor
lesions (complex atypical hyperplasias – CAH), primary tumors, and
metastases.
2. Material and methods
2.1. Patient series
Women diagnosed with endometrial carcinoma at Haukeland Uni-
versityHospital, Norway,were prospectively included during theperiod
2001–2015. Haukeland University Hospital is a referral hospital for
Hordaland County, and the patient series is representative of the Nor-
wegian population due to similar incidence rates and patient character-
istics for this region compared to the whole of Norway [12]. Primary
tumor tissue from 782 patients was collected during hysterectomy
and prepared as formalin fixed and paraffin embedded (FFPE) tissue.
This corresponds to 76% of endometrial carcinoma patients included
in the local biobank during this time period. Cases not represented in
TMAs include inoperable patients, patients with sparse tumor material
in hysterectomy specimen, and cases with poor technical quality of
TMA tissue cylinders. Fresh frozen tissue was collected in parallel
when possible. Clinical information was retrieved frommedical records
as previously described [13], including age at primary treatment, Inter-
national Federation of Gynaecology and Obstetrics (FIGO) stage (ac-
cording to 2009 criteria), histopathological type and grade, and
follow-up data. Biopsies from precursor lesions were obtained from 90
patients diagnosed with CAH. Samples from metastatic tissue were
available for 87 patients (179 lesions in total). All parts of the study
have been approved according to Norwegian legislation, including the
Norwegian Data Inspectorate, Norwegian Social Sciences Data Services
and Western Regional Committee for Medical and Health Research
Ethics (REK 2009/2315). All participants were informed and gave writ-
ten consent prior to inclusion.
2.2. Immunohistochemistry (IHC)
FFPE tissue was used to generate tissue microarrays (TMA) as previ-
ously described [14]. The tumor area with highest tumor content was
identified on hematoxylin and eosin stained slides. Using a custom
made precision instrument (Beecher instruments, Silver Spring, MD,
USA) tissue cylinders (0.6 mm) (three tissue cylinders for primary
tumors and CAHs and one tissue cylinder for metastatic lesions) were
punched out of the donor block and mounted in a recipient paraffin
block. TMAswere stained by automated IHC using a previously published
polyclonal anti-ASRGL1antibody (HPA029725, diluted 1:375) [11], or a
monoclonal anti-ASRGL1 antibody (AMAb90907, diluted 1:1000)
(Both; Atlas Antibodies, Stockholm, Sweden). ASRGL1 staining in tumor
cells was evaluated without considering sub-cellular localization [11]. A
staining index (SI) was calculated for each patient based on all three cyl-
inders by multiplying staining intensity (range 0–3) and area of positive
stained tumor cells (1 ≤ 10%, 2=10–50%, 3 ≥ 50%) as previously reported
[15]. For statistical analyses cases were ranked by staining index, and
categorized into quartiles based on frequency distribution and size of
the subgroups. The upper three quartiles were combined based on simi-
larities in survival, and defined as “ASRGL1 high”. The lower quartile was
defined as “ASRGL1 low”, corresponding to SI: 0–2 (HPA029725) or SI:
0–1 (AMAb90907). Random TMA slides were scored by three indepen-
dent observers (TF, KS and ILT) blinded for patient characteristics and
outcome, and an intraclass correlation coefficient (ICC) was calculated
to assess interrater reliability for each of the two antibodies. The ICC of
HPA029275 score in two groups was 0.71 (95% confidence interval
(CI): 0.64–0.78, n = 126 patients), while AMAb90907 score in two
groups had an ICC of 0.95 (CI: 0.93–0.96, n = 105 patients). Staining
and scoring of estrogen receptor α (ERα) have previously been
described, defining loss of ERα as SI: 0–3 [16].
2.3. Gene expression
RNA was extracted from fresh frozen tissue using the RNeasy Mini
Kit (Qiagen, Hilden, Germany) according to the manufacturer's instruc-
tions. Samples were hybridized to Agilent Whole Human Genome Mi-
croarrays 44 k (Cat. No. G4112F) prior to scanning and normalization
as previously reported [16]. In total, RNAwas extracted from237 prima-
ry tumors. For survival analyses based on mRNA levels patients were
ranked by ASRGL1 expression and divided into quartiles. The cut-off
for low ASRGL1was defined as the lower quartile of cases.
2.4. Statistical analyses
SPSS Statistics software (version 24.0; IBM Corp., Armonk, NY, USA)
was used for statistical analyses. All statistical tests were two-sided, and
P-values ≤ 0.05 were considered statistically significant. ICC estimates
were calculated by a single rater absolute agreement, two-way random
effects model. Analyses of categorical variables were performed using
the Pearson Chi-square test or Fisher's exact test, while continuous var-
iables were evaluated using the Mann-Whitney U test. Disease-specific
survival curves were generated using the Kaplan-Meier method, and
survival between groups was compared using the log rank (Mantel-
Cox) test. Time of primary surgery was used as entry date, and time to
death due to endometrial carcinoma was defined as endpoint. Cox
proportional hazard regression model was used to evaluate the inde-
pendent prognostic impact of ASRGL1 in multivariate survival analyses.
3. Results
782 patients treated for endometrial carcinoma at Haukeland
University Hospital were prospectively included in this study. Of these
patients, 79% (n = 616) were classified as “ASRGL1 high” (Fig.1A) and
21% (n = 166) as “ASRGL1 low” (Fig.1B) when evaluating ASRGL1
expression in primary tumors by IHC. Validation of antibody was per-
formed by staining 607 primary tumors with two different antibodies
(AMAbb90907 andHPA029725). These antibodies had significantly cor-
related scoring indexes (P b 0.001) and similar prognostic value. The ICC
estimate for AMAb90907 (ICC: 0.95, CI: 0.93–0.96) indicates excellent
interrater reliability [17], and was higher than for HPA029725 (ICC:
0.71, CI: 0.64–0.68). AMAb90907 score was therefore selected for
further analyses. LowASRGL1 protein expressionwas significantly asso-
ciatedwith clinicopathological characteristics of aggressive endometrial
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carcinoma such as high age, high FIGO stage, ERα loss and non-
endometrioid histology (P b 0.001 in all) (Table 1). The proportion of
patients with low ASRGL1 expression was particularly high among car-
cinosarcomas and undifferentiated endometrial tumors (71% and 86%,
respectively), but also 8% of patients with endometrioid grade 1–2
tumors expressed low ASRGL1 levels (Table 1). In a univariate survival
analysis, low ASRGL1 level predicted poor disease-specific survival in
the whole patient population (Fig. 1C). ASRGL1 was also found to have
an independent prognostic impact on survival in amultivariate survival
analysis after adjusting for age, FIGO stage, histological type and grade
(Hazard ratio (HR): 1.53, CI: 1.04–2.26, P = 0.031) (Table 2). The
ASRGL1 gene has been reported up-regulated in several cancer forms
and mRNA expression levels might be an alternative prognostic bio-
marker in gene-based applications. A significant overlap between
ASRGL1 mRNA and protein level was observed in 237 patients with
both IHC and microarray data available (P b 0.001) (Fig. 1D), and
patients with low ASRGL1 mRNA expression had significantly worse
5 year disease specific survival (DSS) compared to patients with high
ASRGL1 mRNA expression (5 year DSS of 0.60 and 0.87, respectively,
P b 0.001, Fig. 1E).
ASRGL1 was evaluated by IHC in 90 patients with complex atypical
hyperplasia, a precursor lesion of endometrial carcinoma. ASRGL1
expression was mainly intact in this group, and 70% of patients had
strong positive staining (SI: 6–9). Only one patient (1%) demonstrated
low ASRGL1 level (Fig. 2A). The proportion of lesions with low
ASRGL1 expression increased significantly with higher grade within
the endometrioid endometrial carcinoma subgroup (P b 0.001)
(Fig. 2A). Of the non-endometrioid tumors 56% had low expression of
ASRGL1, which was significantly higher than for the endometrioid
grade 3 tumors (P = 0.012). In the subgroup of endometrioid endome-
trial carcinoma patients where less aggressive disease is presumed
[18], low expression of ASRGL1 was significantly associated with
Fig. 1. Low expression of ASRGL1 predicts poor survival. Immunohistochemical staining of ASRGL1 (AMAb90907), demonstrating “high” (A) and “low” (B) staining index. Low protein
expression of ASRGL1predicts poor disease specific survival in the whole patient population (C). ASRGL1 mRNA and protein expression is found to significantly correlate, using the
Mann-Whitney U test (D), and the quartile of patients with the lowest ASRGL1 mRNA expression have significantly poorer disease specific survival than patients with higher ASRGL1
mRNA expression (E).
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characteristics of aggressive disease (Supplementary Table S1) and poor
disease-specific survival (P b 0.001, Fig. 2B). ASRGL1 was also found to
have independent prognostic valuewithin the endometrioid endometri-
al carcinoma patients after adjusting for age and histologic grade (HR:
2.64, CI: 1.47–4.74, P = 0.001, Table 3). In the non-endometrioid sub-
group ASRGL1 did however not have an independent impact on survival
when adjusted for age and FIGO stage (HR: 1.37, CI: 0.83–2.26, P =
0.226).
ASRGL1 expression was investigated by IHC in 179 metastatic le-
sions from 87 patients with available corresponding primary tumors.
Of these 87 patients, 43% of primary tumors and 77% of metastases
expressed lowASRGL1 levels (Fig. 3A and Supplementary Fig. S1).With-
in the endometrioid subgroup, patients with grade 1 and 2
endometrioid endometrial carcinoma had fewer metastases with low
ASRGL1 level (53% and 44% of lesions, respectively) than grade 3
endometrioid endometrial carcinoma patients (80% of lesions). Overall,
patientswith endometrioid endometrial carcinomahad a lower propor-
tion of metastatic lesions with low ASRGL1 expression compared to pa-
tients with non-endometrioid endometrial carcinoma (63% and 90% of
metastases, respectively, Supplementary Fig. S1). Of 50 patients with
“ASRGL1 high” primary tumors, only 10% had some metastases with
high and some metastases with low ASRGL1 level. 46% of patients had
intact ASRGL1 expression in all metastases, while 44% of patients had
ASRGL1 loss in all metastatic lesions (Fig. 3B). 37 patients had low
ASRGL1 expression in primary tumor, and the majority of these (89%)
also had low ASRGL1 level in all metastatic lesions. 4 patients had high
ASRGL1 expression in some, but not all metastases. None of the patients
with ASRGL1 low primary tumors had high ASRGL1 expression in all
metastatic lesions (Fig. 3C). For patients with more than one available
metastatic lesion, the expression pattern of ASRGL1 was similar be-
tween the different metastases in individual patients in most cases
(Supplementary Fig. S1). Information regarding ERα status in metasta-
ses was included when known, and was available for a total of 158 le-
sions. A similar expression of ASRGL1 and ERα in metastases was
observed. 73% of metastatic lesions with high ASRGL1 levels had intact
ERα, and 72% of lesions with low ASRGL1 had low levels of ERα.
ASRGL1 was more frequently lost in metastatic lesions than ERα (77%
and 60% of lesions respectively, P = 0.001, Supplementary Fig. S1).
4. Discussion
New, robust biomarkers are needed to tailor treatment for individual
endometrial carcinoma patients. To achieve clinical implementation,
novel biomarkers should be validated in independent studies with suffi-
cient number of patients to ensure statistical power. Validation studies
should also be performed in patient groups that are representative for
the population where the biomarker potentially will be used [19]. In
the current study we validate loss of ASRGL1 expression as a prognostic
marker for poor survival in endometrial carcinoma, in a large, indepen-
dent, population-based patient cohort. This is the first study investigating
the prognostic potential of ASRGL1 expression in a prospective setting in
endometrial carcinoma, as ASRGL1 previously only has been explored in
retrospectively collected cohorts with lower number of patients [11].
In the present study ASRGL1 expression was evaluated using the
staining index, where low expression is defined as 0–1 and high
Table 1
ASRGL1 protein expression related to clinicopathological variables in 782 patients with
endometrial carcinoma.
Variable N ASRGL1 P-value (x2)
High n (%) Low n (%)
Age 782 b0.001
b66 405 341 (84) 64 (16)
≥66 377 275 (73) 102 (28)
FIGO stage 2009 782 b0.001
I–II 659 551 (84) 108 (16)
III–IV 123 65 (53) 58 (47)
Histologic type 782 b0.001
Endometrioid 635 551 (87) 84 (13)
Clear cell 29 15 (52) 14 (48)
Serous 70 38 (54) 32 (46)
Carcinosarcoma 34 10 (29) 24 (71)
Undifferentiated 14 2 (14) 12 (86)
Histologic grade 623 b0.001
Grade 1–2 511 471 (92) 40 (8)
Grade 3 112 68 (61) 44 (39)
Metastatic lymph nodes 630 b0.001
Negative 559 457 (82) 102 (18)
Positive 71 37 (52) 34 (48)
Ploidy 490 b0.001
Diploid 381 302 (79) 79 (21)
Aneuploid 109 57 (52) 52 (48)
Myometrial infiltration 779 b0.001
b50% 483 410 (85) 73 (15)
≥50% 296 205 (69) 91 (31)
ERα 741 b0.001
Positive 555 514 (93) 41 (7)
Negative 186 75 (40) 111 (60)
Abbreviations: Asparaginase-like protein 1 (ASRGL1), Estrogen receptorα (ERα), Interna-
tional Federation of Gynaecology and Obstetrics (FIGO).
Missing information on histologic grade for 12 patients, metastatic nodes for 152 patients,
ploidy for 292 patients, myometrial infiltration for 3 patients, and ERα status for 41
patients.
a Endometrioid cases only.
Table 2
Multivariable survival analyses of endometrial carcinoma patients according to the Cox’ proportional hazards regression model.
Variable na Unadj.HR 95% CI P-value Adj.HR 95% CI P-value
Age (mean = 65) b0.001 b0.001
770 1.05 1.04–1.07 1.03 1.02–1.05
FIGO stage b0.001 b0.001
I/II 648 1 1
III/IV 122 8.77 6.17–12.45 5.08 3.49–7.39
Histologic type b0.001 0.001
Endometrioid 623 1 1
Non-endometrioid 147 6.73 4.71–9.60 2.29 1.42–3.70
Histologic grade b0.001 0.050
1/2 511 1 1
3 259 6.11 4.16–8.96 1.73 1.00–2.97
ASRGL1b b0.001 0.031
High 604 1 1
Low 166 4.10 2.89–5.82 1.53 1.04–2.26
a Cases with data available for all variables included in the univariate analyses (N= 770).
b Evaluated in hysterectomy samples by IHC (high = 2–9, low = 0–1).
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expression as 2–9. An earlier study defined positive staining in N75% of
cells as cut-off for high ASRGL1 expression regardless of staining inten-
sity [11]. The fact that different scoringmethods and cut-offs for ASRGL1
demonstrate prognostic impact supports its robustness as a prognostic
marker in endometrial carcinoma.
Low ASRGL1 protein expression has been linked to aggressive
disease and poor survival in endometrial carcinoma, and is reported to
be an independent prognostic marker in endometrioid endometrial
carcinoma [11]. This is consistent with our findings, and we are the
first to demonstrate that ASRGL1 has independent prognostic value
also in the whole patient population.
No IHC biomarkers are currently clinically used to recommend adju-
vant chemotherapy in endometrial carcinomapatients [20–22], and risk
stratification is based on traditional parameters such as FIGO stage and
histological grade. Low ASRGL1 expression can potentially be used as a
biomarker aiding in the selection of patients that may benefit from ad-
juvant treatment. Patients with grade 1–2 endometrioid endometrial
carcinoma are generally assumed to have low risk disease and are not
recommended for adjuvant therapy [20]. Interestingly, 8% of the
patients in our cohort with grade 1–2 endometrioid endometrial carci-
noma have low ASRGL1 level, and it is tempting to speculate whether
these patients could benefit from more extensive treatment.
Chemotherapy is often related to adverse effects and reduced quality
of life, and biomarkers that can identify patients that may not benefit
from additional treatment could potentially improve quality of life for
those patients as well as reduce medical costs. We observed that high
expression of ASRGL1 is associated with a favorable outcome, both in
the endometrioid subgroup and in the whole patient cohort. It would
be interesting to further explore if high ASRGL1 expression could be
used to select patients that may be spared from the detrimental effects
associated with adjuvant treatment.
Loss of the hormone receptor ERα is associated with aggressive
disease and poor survival in endometrial carcinoma patients [23,24],
and ERα is currently one of the best validated prognostic molecular bio-
markers in endometrial carcinoma [25]. An estrogen response element
has been identified in the promotor of the ASRGL1 gene [8], suggesting
a link between this steroid hormone and expression of ASRGL1. A po-
tential regulatory role of estrogen on ASRGL1 expression could explain
the association between hormone receptor status and ASRGL1 levels
found in both primary tumor and metastatic lesions in our study.
ASRGL1 status inmetastases has not previously been investigated. In
the current study we describe the protein expression of ASRGL1 in 179
metastatic lesions and their corresponding primary tumors from 87
patients, also linking this to histology and ERα status. Interestingly, in
most cases where primary tumor has a low ASRGL1 level, ASRGL1
expression is also low in corresponding metastases. In most patients
with multiple metastases, similar expression of ASRGL1 is found in all
metastatic lesions from the same individual. This is in contrast to
hormone receptors, where the expression pattern of metastatic lesions
in individual patients seems to be more heterogeneous [26]. 4 patients
with ASRGL1 low primary tumors had high expression of ASRGL1 in
some but not all metastases. Possible explanations include that these le-
sions originate from cells that metastasized at an earlier time point
where primary tumor expressed ASRGL1, or that small ASRGL1 positive
regions in primary tumor were missed when collecting biopsies or
selecting areas for preparation of TMAs. It must be emphasized that
our study only includes sampled metastatic lesions with corresponding
primary tumors. Patients may have metastases that are surgically un-
available or that have not been sampled for other reasons. However,
wefind this to be interestingdescriptive observations that should be ex-
plored further in future studies.
ASRGL1 is demonstrated to degrade both ʟ-asparagine and
isoaspartyl peptides in vitro [5], but the functional role in normal and
cancerous cells is not known. Asparagine is reported to suppress
apoptosis [27], and isoaspartyl peptides generated in proteins by non-
enzymatic damage leads to misfolding, dysfunction and reduced degra-
dation [5,28]. This indicates that loss of ASRGL1 function could lead to
both elevated cellular asparagine levels and accumulation of dysfunc-
tional proteins. Investigating the cellular effects of ASRGL1 activity as
well as molecular mechanisms related to loss of ASRGL1 expression
would be interesting, and could beperformed through in vitro and even-
tually also in vivo studies. ʟ-Asparaginase has been used to treat acute
lymphoblastic leukemia and Non-Hodgkin lymphoma for several
Fig. 2.ASRGL1 protein level decreaseswith dedifferentiation, and predicts survival in EEC. The proportion of tumorswith lowASRGL1 expression is increasingwith higher gradewithin the
endometrioid endometrial carcinoma patients, and is higher in non-endometrioid patients compared to endometrioid grade 3 patients. Numbers on bars represent the number of patients
with low ASRGL1. P-values were calculated using the Fisher's exact test (A). Low protein expression of ASRGL1 is associatedwith poor survival in patients with endometrioid endometrial
carcinoma (B). Abbreviations: CAH: complex atypical hyperplasia, G: grade, NE = non-endometrioid. *Information on grade missing for 12 patients.
Table 3
Multivariable survival analyses of endometrioid endometrial carcinoma patients accord-
ing to the Cox’ proportional hazards regression model.








1/2 510 1 1
3 112 3.28 1.96–5.47 2.12 1.21–3.70
ASRGL1b b0.001 0.001
High 539 1 1
Low 83 3.40 1.99–5.79 2.64 1.47–4.74
a Cases with data available for all variables included in the univariate analyses (N=622).
b Evaluated in hysterectomy samples by IHC (high = 2–9, low = 0–1).
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decades, and the therapeutic potential of ʟ-asparaginase is now being
explored in several solid tumors [29–32]. As ASRGL1 is proposed to dis-
play proteolytic activity against ʟ-asparagine and loss of this enzyme is
associated with aggressive disease and poor prognosis, ʟ-asparaginase
could potentially be a candidate drug for treatment of endometrial
carcinoma.
We have validated ASRGL1 as a strong prognostic marker in endo-
metrial carcinoma in a prospective setting, and find that loss of both
mRNA and protein expression predicts poor outcome. Low ASRGL1 ex-
pression had independent prognostic value both in the endometrioid
subgroup and in the endometrial carcinoma population in general,
and its clinical utility as a prognosticmarker should be further evaluated
through clinical trials.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2017.10.025.
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Supplementary Table S1. ASRGL1 protein expression related to 
clinicopathological variables in 635 patients with endometrioid endometrial 
carcinoma. 






High n (%) 
 
Low n (%) 
 
P-value (x2) 
Age                                          635                                                                   0.475 
< 66 363 318 (88) 45 (12)  
≥ 66 272 233 (86) 39 (14)  
FIGO stage 2009                    635                                                                  <0.001 
I-II 561 505 (90) 56 (10)  
III-IV  74        46 (62) 28 (38)   
Histologic grade                    623                                                                  <0.001 
Grade 1-2 511 471 (92)         40  (8)  
Grade 3 112   68 (61)  44 (40)  
Metastatic nodes                   506                                                                  <0.001 
Negative     466 414 (89)  52 (11)  
Positive       40  25 (63)        15 (37)  
Ploidy     381          0.007 
Diploid     322 275 (85) 47 (15)  
Aneuploid 59   42 (71) 17 (29)  
Myometrial infiltration           634                                                                  <0.001 
<50%     406 371 (91) 35  (9)  
≥50%     228 180 (79)  48 (21)  
ERα                                         602                                                                   <0.001 
Positive     503 476 (95)  27  (5)  
Negative       99   50 (51)  49 (49)  
 
Abbreviations: Asparaginase-like protein 1 (ASRGL1), Estrogen receptor α (ERα), 
International Federation of Gynaecology and Obstetrics (FIGO). 
 
Missing information on histological grade for 12 patients, metastatic nodes for 129 
patients, ploidy for 254 patients, myometrial infiltration for 1 patient, and ERα status 
for 33 patients. 
 
 
“ASRGL1 high” primary tumor “ASRGL1 high” ERα positive metastasis
“ASRGL1 low” primary tumor “ASRGL1 low” ERα negative metastasis
Grade 1 (n = 11)
Grade 2 (n = 20)
Grade 3 (n = 17)
Endometrioid EC 
Non endometrioid EC 
Serous (n = 20)
Carcinosarcoma (n = 9) Clear  cell (n = 6) Undifferentiated
       (n = 3)
*
Supplementary figure S1. ASRGL1 status in individual metastatic lesions.
Expression pattern of ASRGL1 in sampled metastatic lesions with corresponding
primary tumors from patients diagnosed with endometrial carcinoma. Rectangles
represent primary tumorsof individual patients and each line of circles one
metastasis, illustrationg the status of ASRGL1 (purple) and ERα (yellow) for that 
lesion. *Information on grade missing for one patient. Abbreviations: EC =
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